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Poorly soluble drugs are often a challenging problem in drug formulation. Reducing the particle 
size of the drug to a nano-scale leads to an increased surface area-to-volume ratio, increased 
dissolution velocity and adhesiveness, and improved in vivo performance of poorly soluble drugs. 
Wet media milling is one of the most popular techniques to prepare the nanocrystals. The aim of 
this thesis was to optimize the preparation conditions and characterization methods of 
nanosuspensions for poorly water-soluble drug compounds, then formulate the nanosuspensions 
into suitable pharmaceutical dosage forms, and finally test the efficacy in in vivo. 
Firstly, basic research on the preparation and characterization of nanosuspensions was done 
using the wet milling technique and poorly water-soluble drugs as model compounds. The various 
milling parameters, including the milling time, diameter of milling balls, stabilizer type and 
concentrations, were investigated. The particle size, size distribution and stability of 
nanosuspensions were considered as the important parameters to evaluate the milling conditions. 
The drug nanocrystals manufactured at the optimal milling environment exhibited significantly 
increased dissolution rates, good stability and kept a crystalline state. 
Secondly, the importance of particle size on dissolution was determined. The conventional 
dissolution method can effectively discriminate the milled and unmilled samples, but it fails to 
discriminate the dissolution profiles of nanosuspensions with different particle sizes. A novel 
condition, i.e. the sample concentration in the dissolution medium is close to the apparent saturation 
solubility of the drug, were found to discriminate the dissolution profiles of nanosuspensions. 
Thirdly, “nanos-in-micros” structure for suitable pharmaceutical formulations, e.g. tablet or 
pulmonary products was set up. The structure is that drug nanocrystals are buried inside 
microparticle carriers, in which the mannitol and crystalline L-leucine were as matrix and outer 
layer formers, respectively.  “Nanos-in-micros” structure avoids problems in further formulation of 
nanopowders, such as poor flowability and aggregation/sinter, meanwhile functionality of 
individual nanoparticles in microparticles are remained, such as fast dissolution.  
Finally, the efficacy of nanocrystal formulations in vivo was tested. Brinzolamide 
nanosuspensions were prepared in buffers and formulated for ocular administration in order to 
reduce the intraocular pressure in rats. The nanocrystal formulations exhibited a low cytotoxicity 
and significant reduction in intraocular pressure compared to the physiologic salt solution and 
untreated group. 
In conclusion, the nanosuspensions of poorly water-soluble drug can be easily produced by the 
wet milling technique when the choice of stabilizers and milling parameters are appropriate. The 
nanosuspensions were successfully formulated and exhibited a good in vivo performance. More 
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In drug discovery the combinatorial chemistry and high throughput screening often leads to new 
chemical entities with high molecular weight and increasing lipophilicity and therefore decreasing 
aqueous solubility [1]. It is estimated that nearly 40% of the drugs in the pipeline have solubility 
problems and 60% of new drugs are poorly water-soluble [2]. To achieve its pharmacological 
activity, drug must be present in the dissolved state at the site of absorption in oral administration. 
The poor aqueous solubility of drugs resulting in poor oral bioavailability has always been a 
challenging problem in pharmaceutical research. 
Many approaches have been developed to improve the drug solubility in aqueous phase, such as 
salt formation, co-solvents, complexes with cyclodextrins, changing its solid state. Decreasing the 
particle size into nanometre is a promising approach to improve the apparent saturation solubility, 
dissolution rate and oral bioavailability of hydrophobic drugs (BCS (biopharmaceutical 
classification  system)  Class  II,  in  some  cases  also  with  BCS  Class  IV  drugs).  Drug  nanocrystals,  
consisting of pure drugs and a minimum of surface active agents required for stabilization, are 
carrier-free submicron colloidal drug delivery systems with a mean particle size in the nanometre 
range, typically between 10 and 1000 nm [3]. Compared to other nanotechnological approaches, 
nanocrystals have a very high drug loading, as the particle core is composed of pure drug material.  
The wet pearl milling technique is an important top-down method for preparing 
nanosuspensions. At the moment, approximately twenty nanocrystal products are on the market and 
most of them are made by the wet milling technique. However, there are still problems with the wet 
milling. There is no single versatile stabilizer suitable for all drug compounds and different drugs 
require their optimal stabilizers. Inadequate systematic understanding on the interactions between 
stabilizers and drugs is available. Although the wet milling technique has been thought as a simple 
milling process for size reduction, actually multidisciplinary knowledge, including knowledge of 
grinding mechanism, breakage kinetics of nanocrystals, the physical background of crystal stability, 
formulation processing and factors affecting the drug fate in vivo are all necessary to fully 
understand the technique [4]. In addition, with the number of nanoformulations increasing, 
conventional dissolution methods are not good enough for discriminating the dissolution profiles 
between nano-products since the very rapid dissolution in sink conditions masks the differences.  
Nanocrystals are considered as versatile platform for administration through various routes, such 
as oral, parenteral, ophthalmic, transdermal and pulmonary delivery. It was reported that 
pharmaceutical nanocrystals have good performances in vivo, such as improved bioavailability, 
potential site-special drug delivery, fed/fasted state independent bioavailability, and suitability for 
drugs with a narrow absorption window. 
This thesis focuses on manufacturing and formulating the nanosuspensions for poorly water-
soluble drug compounds. Our aims were to find out the optimal manufacturing conditions and basic 
properties of nanosuspensions. The effect of preparation parameters on particle size, size 
distribution and stability, including milling time, stabilizer type and concentration, and the diameter 
of the milling balls, were evaluated. The basic properties of nanosuspensions such as morphology, 
dissolution rate and solid state were characterized. Slowing down the dissolution rate was used in 
this thesis to discriminate between the dissolution profiles of nanosuspensions with different 
particle sizes. Furthermore, the formulations of nanosuspensions were developed. The 
nanosuspensions were dried in an aerosol flow reactor to generate the microparticles, which can be 
used for example for tablet or pulmonary drug delivery. Finally, brinzolamide nanocrystal 
formulations were made for ocular drug delivery in order to reduce the intraocular pressure in vivo. 
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2 Review of the literature 
2.1 Poorly water-soluble drug compounds 
When drug discovery and medicinal chemistry moved from wet chemistry to combinatorial 
chemistry and high throughput screening in the mid-1990s, the properties of newly developed 
chemical entities shifted towards higher molecular weight and increasing lipophilicity [5]. Drug 
dissolution is a prerequisite to drug absorption and clinical response for orally administered drugs 
[6]. However, it was estimated that 40% of the drugs in the pipelines have solubility problems and 
60% of new drug molecules are poorly water soluble [7, 8], which generates many problems in drug 
research and development (Table 1).  
Table 1 Major issues associated with poorly water-soluble compounds [9]. 
? Poor bioavailability 
? Inability to optimize lead compound selection based on efficacy and safety 
? Fed/fasted variation in bioavailability 
? Lack of dose-response proportionality 
? Suboptimal dosing 
? Use of harsh excipients, i.e., excessive use of cosolvents and other excipients 
? Use of extreme basic or acidic conditions to enhance solubilization 
? Uncontrollable precipitation after dosing 
? Noncompliance by the patient, i.e., inconvenience of the dosage platform 
To overcome the problems arising from the limited solubility and dissolution rate, intrinsic 
modification of chemical or physical properties of drug molecules and extrinsic modification of 
drug formulations can be used. The former includes salt complexes, prodrug formation, changes in 
the solid state, and particle size reduction. The formulation strategy includes cosolvents (e.g. water-
ethanol), solubilization in surfactant systems, solid dispersions and formation of water-soluble 
complexes (e.g. ?-cyclodextrins). Good overviews of these strategies for poorly water soluble drugs 
have been presented in recent reviews (refs. [10] and [11]). However, excipient-related toxicity or 
unwanted side-effects should be cautioned when the excipients, such as surfactants, polymers and 
organic solvents, are used to enhance the solubility of the drug. For example, in the formulation of 
Taxol®, anti-cancer drug paclitaxel is dissolved in the blend of ethanol and Cremophor® EL 
(polyoxyethylated castor oil) (1:1), which causes serious hypersensitivity reactions [12]. 
2.2 Nanocrystalline particles 
In pharmaceutical sciences term drug nanocrystals means particles having a solid, usually 
crystalline drug core in the nanometer size range and an outer layer consisting of a stabilizer. 
Nanocrystals can also be named as drug nanoparticles and sometimes even amorphous drug 
nanoparticles are called nanocrystals. Since pharmaceutical nanocrystals are normally prepared in 
either an aqueous solution or non-aqueous solvent medium, the term nanosuspension is also often 
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used as synonymous to nanocrystals, meaning a sub-micron colloidal dispersion of pure drug 
particles, which are stabilized by surfactants, polymers, or both [13].  
2.2.1 Properties of nanocrystals  
2.2.1.1 Increased solubility and dissolution velocity 
Solubility is determined by balance of intermolecular forces between the solvent and solute, and the 
entropy change that accompanies the solution. According to an IUPAC (International Union of Pure 
and Applied Chemistry) definition, solubility is the analytical composition of a saturated solution 
expressed as a proportion of a designated solute in a designated solvent [14]. The extent of the 
solubility of a substance in a specific solvent is measured as the saturation concentration. Under 
certain conditions, the saturation concentration can be exceeded to give a so-called supersaturated 
solution, which is metastable. Apparent solubility is the solubility for the thermodynamically less 
stable form in a special situation, which differs from the thermodynamic solubility; e.g. amorphous 
or metastable polymorphs, nanocrystals, cyclodextrin complexes. And, correspondingly, apparent 
saturation  solubility  is  the  saturation  solubility  for  these  systems.  In  dissolution,  a  solute  forms  a  
solution in a solvent. The dissolution rate quantifies the speed of the dissolution.    
How the apparent saturation solubility and dissolution velocity are increased in the case of 
nanocrystals is illustrated in Fig.1. Assuming that the drug nanoparticles have spherical shape, the 
surface area-to-volume ratio of a particle is 3/r, where, r is the radius of the particle [15]. Thus, the 
reduction in particle size increases the surface area-to-volume ratio (Fig.1.1). Meanwhile, the total 
surface area of particles increases when one large particle is divided into many nanoparticles. The 
increased surface area accelerates the dissolution rate according to the Noyes-Whitney equation (see 
below). 
The apparent saturation solubility (cs) of drugs not only depends on the drug compound, the 
dissolution medium and temperature, but also on the particle size when it is below 1µm [16]. 
According to the Ostwald-Freundlich equation, the vapor pressure of liquid droplets changes due to 
the increasing curvature of the droplet/vapor interface with decreasing droplet radius. As the droplet 
radius decreases, the high droplet surface curvature leads to a higher vapor pressure. The process of 
molecule transfer from liquid droplet to a gas phase is similar with the process of molecule transfer 
from  solid  phase  (nanocrystals)  to  liquid  phase  (dissolution  medium).  The  vapor  pressure  is  
equivalent to the dissolution pressure [16]. Thereby the apparent saturation solubility of 
nanocrystals is increased by the high surface curvature and dissolution pressure (Fig.1.2). Increased 
apparent saturation solubility further accelerates the dissolution rate. 
In  Fig.1.3,  the  diffusional  distance  (h) around the particles decreases for very small particles, 
leading to a high concentration gradient around particles by (cs-cx)/h. Combining all influencing 
factors and according to the Noyes-Whitney equation, the dissolution velocity of nanocrystals is 
remarkably improved. Anderberg et al. [17] reported that at the particle size of 1 µm the intrinsic 
dissolution rate is very fast and that further decrease in size did not markedly increase oral 
adsorption. Jinno et al. [18] estimated the 50% dissolution times (T50%) of nanosuspensions based 
on the simulated curves. The results indicated that the dissolution rates of nanosuspensions with 
particle size of 0.22 µm would be 5100-fold greater than that of 13 µm in the same dissolution 
conditions. Particle size reduction is an effective and safe approach to improve the apparent 
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saturation solubility and dissolution velocity of poorly water-soluble drug compounds, while 









Figure 1 Transfer of microcrystals to nanocrystals leads to an increase in surface area (upper). Increase in 
apparent saturation solubility cs, decrease in diffusional distance h and increase in the concentration 
gradient cs?? cx /h all increase the dissolution velocity dc/dt [19]. 
2.2.1.2 Increased adhesiveness 
Once nano- and microparticles are taken orally, particles are faced with at least three different 
pathways: (i) capture by gut-associated lymphoid tissue; (ii) mucoadhesion; and (iii) direct faecal 
elimination after gastrointestinal transit [20]. For nanoparticles, the mucous gel layer is a porous 
structure (Fig.2 A). Nanoparticles can quickly penetrate deeply into the gel layer and closely contact 
with the mucous network. The adsorption isotherm shows linear increase with particle 
concentration. However, for microparticles, the mucosal gel layer resembles more like a smooth 
surface, rather than porous, since the particle size is too large to enter the mucosal gel layer (Fig.2 
2. Increase in apparent saturation solubility cs 1. Increase in surface area A 
3. Decrease in diffusional distance h and thus  
    Increase in concentration gradient (cs-cx)/h 
4. Increase in dissolution velocity dc/dt 
described by: Noyes-Whitney equation 
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B). The adsorption follows a Langmuir isotherm [20]. The size dependency of the particle 
deposition has been found [21]. Durrer et al. [22] quantified adsorbed poly (styrene) latexes on rat 
intestinal mucosa. The adsorption results showed that 90% of equilibrium was reached after 10 min 
for  a  particle  size  of  230  nm,  20  min  for  a  size  of  320  nm  and  30  min  for  a  size  of  670  nm.  
Therefore, nanoparticles increased the adhesiveness capability and shortened the adsorption time. 
The increased adhesiveness of nanoparticles prolongs the contact time and retention time to 
gastrointestinal tract (GIT) membrane [23, 24].  Meanwhile, the diffusion distance of nanoparticles 
to the GIT membrane is decreased, and then the concentration gradient becomes larger, which 
enhances the passive transport of the drug molecules [25]. In addition, particles captured by the 
mucosal layer are protected from denaturation in the gastro-intestinal lumen [20].  
 
 
Figure 2 Adsorption isotherm shapes and corresponding adsorption models. A: case of particles < 1 µm. B: 
case of particles > 1µm [20]. 
2.2.2 Nano-sized techniques 
There are two approaches to produce nanocrystals: top-down approaches and bottom-up 
approaches. In top-down methods large particles are broken down to small ones (e.g. wet milling 
and high pressure homogenization (HPH)), while bottom-up methods rely on a process of dissolved 
6 
 
drug molecules building up to nano-sized particles (e.g. precipitation). Table 2 shows an overview 
of various technologies for nanocrystal preparations. 
Table 2 Overview of the technologies utilized in nanocrystal formulations (modified after the reference [26]) 
Technique Nanocrystal Company 
Precipitation  Bottom-up Hydrosol®  Sandoz/Novartis  
Precipitation  Bottom-up Nanomorph® Soligs/Abbott  
Wet milling Top-down Nanocrystal® NanoSystems/élan 
HPH Top-down IDD-P® SkyePharma Canada Inc. 
HPH Top-down Dissocubes® SkyePharma  
HPH Top-down Nanopure® PharmaSol 
Combination - NanoEdge® Baxter 
Combination - smartCrystal® PharmaSol Berlin/Abbott  
2.2.2.1 Bottom-up techniques 
The basic idea of bottom-up techniques for preparation of nanosuspensions is that dissolved drug 
molecules precipitate from the solvent and grow up to nanoparticles. Nucleation and crystal growth 
are the two main steps for nanocrystal formation. List and Sucker in 1988 first reported the 
preparation of “hydrosol” by controlled precipitation method, with the intellectual property owned 
by Novartis (previously Sandoz) [27]. Later, Nanomorph® technology as another precipitation 
method was reported to be able to prepare stable amorphous drug nanoparticles. This technique is 
owned by the company Soliqs/Abbott (previously Knoll/BASF) [16] (Table 2).  
Precipitation technologies can be broadly classified into four categories: precipitation by liquid 
solvent-antisolvent addition, precipitation in presence of supercritical fluid, precipitation by 
removal  of  solvent  and  precipitation  in  presence  of  high  energy  processes  [28].  Among  them,  
precipitation by liquid solvent-antisolvent addition is the simplest and most common method. The 
drug compound dissolved in a solvent is mixed with a miscible antisolvent under stirring or 
sonication. The supersaturated drug in the antisolvent quickly creates a large amount of nuclei, and 
then the nuclei grow to the nanoparticles. Agitation and ultrasound is a feasible mixing method to 
accelerate molecular diffusion and mass transfer, which controls the nucleation and crystallization 
processes [29]. Stabilizers should be added in solvent or antisolvent to prevent the molecular 
association and crystal growth. Many experimental parameters can affect the results of nanocrystals, 
such as the drug concentration in solvent, volume ratio of antisolvent to drug solution, power input 
(the stirring speed or ultrasonication time), precipitation temperature and stabilizers [30, 31]. The 
choice of the antisolvent is important since it determines the supersaturation degree of the drug. The 
high level of supersaturation would lead to a fast nucleation rate and small nucleus size. That large 
amount of nuclei are created at the same time and that the nuclei grow simultaneously, are 
preconditions  to  produce  the  small  crystals  with  the  same  size  [32].  Water  is  mostly  used  as  the  
antisolvent for poorly water soluble drugs, but in some cases both the solvent and the antisolvent 
can be organic in nature [33]. Precipitation in the presence of supercritical fluids can be performed 
by RESS (rapid expansion of supercritical solution), RESOLV (rapid expansion of a supercritical 
solution into a liquid solvent) or SAS (supercritical antisolvent) techniques [28]. Mostly utilized 
supercritical fluid for pharmaceutical applications is CO2. 
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Other bottom-up techniques for preparing the nanosuspensions have been reported. Mou et al. 
[34] utilized an acid-base neutralization reaction to prepare itraconazole nanosuspensions, which is 
based on the pH-dependent solubility of the drug. Briefly, the drug dissolved in hydrochloric acid 
solution and ethanol (1.10, v/v) were added to the sodium hydroxide solution under stirring until the 
solution was neutralized. Ali et al. [35, 36] prepared hydrocortisone nanosuspensions using a 
microfluidic nanoprecipitation process. The drug dissolved in organic solvent and antisolvent 
phases (e.g. water) containing stabilizers were flowed in parallel from the microchannels and 
nucleoli occurs in the diffusion layer when the molecules diffuse across the interface between 
fluids. Liquid atomization based techniques, such as spray drying [37], electrospraying [38] and 
aerosol flow reactor [39], can be used for producing drug nanoparticles. In aerosol flow reactor 
method [39], the drug solution was atomized using a collision-type air jet atomizer and the droplets 
were dried at high temperature companying the solvent evaporation. However, the bottom-up 
techniques are not widely applied for drug nanocrystal production nowadays. 
2.2.2.2 Top-down techniques 
Wet pearl milling is a typical top-down technique. The pearl milling technique (Nanocrystal®) was 
developed by Liversidge et al. in 1990 [40] and was formerly owned by company NanoSystems, 
currently owned by Élan Drug Delivery Systems [41]. Milling chamber filled with milling pearls, 
drug, stabilizer and dispersion media (e.g. water, buffer or organic solvent) are rotated in a milling 
machine  at  a  very  high  speed.  Under  the  movement  of  milling  pearls,  the  collisions  of  the  drug  
particles with milling pearls, milling chamber and other drug particles, together with high shear 
forces, fracture the drug crystals into nanosized particles. The common materials for the milling 
pearls include zirconium oxide, stainless steel, glass or highly cross-linked polystyrene resin. The 
process can be performed in batch or continuous modes. The range of milling time is from 30-60 
min to several days for a batch of nanosuspensions, depending on the milling devices, milling 
parameters, batch size and components. The long duration of milling process increases the risk of 
microbial growth, instability (e.g. degradation) and costs. 
Many factors affect the milling results, including the properties of the drug (e.g. hardness and 
density),  concentration  and  type  of  stabilizer,  viscosity  of  suspensions,  amount  of  drug  in  the  
milling vessel, amount, diameter and density of milling pearls, and milling parameters (milling 
speed and time) [42-44]. The hardness and density of the milling pearls and milling chamber must 
be greater than the materials being ground. Luckily, most of active pharmaceutical ingredient (API) 
crystals are relatively brittle. The size of the milling pearls vary from less than 0.1 mm to 20 mm. 
Generally, the smaller milling pearls can induce finer nanoparticles because of the large number of 
contact points; but too small pearls, e.g. 0.03 or 0.015 mm, are not good for milling, because their 
light weight cannot supply with the sufficient impact energy for the drugs [45].  Larger number of 
milling pearls with high density is beneficial for getting fine particles. Longer milling time and 
higher speed increase the percentage of fine particles, but in some cases no change or even increase 
in the particle size were found with the longer milling times. Higher speed reduces the milling time. 
A minimum drug filling quantity is required to avoid the wear to the grinding balls and chamber, 
while a high drug concentration is good for milling attributing to the increased collision probability 
between the  drug  particles.  A normal  drug  concentration  in  the  milling  chamber  ranges  from 1  to  
400 mg/ml.  
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The merits and demerits of the wet milling technique are listed in Table 3. This technique is 
suitable for commercialization due to its advantages, e.g. avoid organic solvents, ease of scale-up 
and high efficiency of drug loading. Polymorphic transition of drug during the wet milling process 
is in most cases not an issue and the drug crystallinity remains intact, providing a good stability and 
shelf life [46]. Contamination from the erosion of grinding pearls is the main problem in the milling 
process. Grinding media fragments were found in the milled samples [31]. Using milling pearls 
coated with highly cross-linked polystyrene resin can minimize the erosion [47], which is currently 
applied in NanoCrystal Technology. Another problem is that the drug product adheres to the surface 
of milling vessel and milling pearls, which cause undesirable drug losses. The drug loss is a big 
issue for very expensive drugs and limited quantities of new chemical entities, like the drug 
development in preformulation phase [48]. 
Table 3 The merits and demerits of wet milling, HPH and precipitation techniques. 
 Merits Demerits 
Milling - Useful for drugs that are poorly soluble in 
aqueous and non-aqueous solvent 
- Avoids organic solvents 
- Ease of scale-up  
- Little batch to batch variation 
- Narrow size distribution of nanoparticles 
- High efficiency of drug loading 
- Expensive manufacturing equipment 
- Intensive-energy use with long milling 
times 
- Potential instability of drugs induced by 
high shear and temperature 
- Contamination from the grinding media 
- Undesirable drug loss 
HPH - Same as with wet milling 
 
- Micronized drug particles needed  
- Suspension formation need 
- Potential erosion and contamination 
from the machine 




- Low cost  
- Low energy-input  
- Simple operation 
- Common equipment  
- Possible for continuous production  
and scale-up 
- Incomplete removal of toxic solvents  
- Difficult to choose the solvent and 
antisolvent 
- Potential particle growth  




The high-pressure homogenization (HPH) is another basic disintegration technology for 
nanocrystal production. Two homogenizer types normally applied are the piston-gap homogenizer 
(e.g. APV Gaulin, Avestin, etc.) and microfluidizer homogenizer (Microfluidics, Inc.) 
In the piston-gap homogenizer, the homogenization in water (DissoCubes® technology) was 
invented by Müller et al. in 1994 [49]. Before homogenization, the particle size of raw drug 
powders (or dispersed in an aqueous surfactant solution) is firstly reduced into microparticles using 
jet-mill [41], basic homogenizer [50, 51], sonication [52] or mortar and pestle [53], which 
effectively avoids blocking the very small homogenization gap (approximately 25 µm). When the 
micronized  suspensions  contained  in  a  cylinder  with  a  diameter  of  3  cm (for  APV LAB 40)  pass  
through a very thin gap (about 25 µm), the liquid boils because the static pressure of liquid is 
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decreased to a lower value than the vapor pressure of the liquid at room temperature. As a result, 
formation and implosion of gas bubbles, cavitation, in the homogenization gap produces particle 
breakage. The strong cavitation forces, high shear forces and the collision of the particles against 
each other act as the main forces to produce nanocrystals. The particle size and size distribution of 
nanosuspensions are related to homogenization pressure, cycle number and hardness of the drugs. 
Pardeike et al. [54] prepared PX-18 (2-N,N-Bis(oleoyloxythyl)amino-1-ethanesulfonic acid) 
nanosuspensions using the HPH method. An exponential decrease rather than a linear decrease in 
particle size was found with the increasing homogenization cycle number. It indicated that the raw 
material containing more weak points (imperfections) is easy to break. When smaller particles are 
formed, the particles are more perfect and more energy is needed to break them.  
The second generation of piston-gap homogenizers was named Nanopure® technology, which 
homogenizes in non-aqueous media. For some purposes and administration routes, the drug 
nanocrystals are needed to be dispersed in water-free media (oils) to be used as soft gelatin capsules 
or isotonic suspensions (water-glycerol mixtures) for intravenous (i.v.) injection, or water-ethanol 
mixtures for easy drying. The cavitation effect is limited in this case since the static pressure is not 
sufficiently lower than the vapour pressure of dispersion media. The details of HPH method were 
described in a recent review [26].  
Microfluidizer homogenizers are based on a jet stream principle, in which the drug suspension 
passes through the designed interaction chambers at a high pressure. Two types of homogenization 
chambers divided by the flow direction of suspensions that have been used are Z-type and Y-type. 
The liquid streams with supersonic velocities turbulent in channels with cross-sections smaller than 
a human hair and impinge against each other and against the chamber wall [55]. The particle size is 
reduced by the high-shear forces, turbulence, and impaction, as well as cavitation. The disadvantage 
of this technology is wide size distribution, i.e. nanosuspensions contain a relatively large fraction 
of microparticles (especially for hard drugs) [56]. However, Hao et al. [57] studied the preparation 
of Amoitone B nanocrystals using the microfluidization technology. Fine nanosuspensions with a 
diameter of 256 nm and polydispersity index (PI) of 0.206 were obtained after the homogenization. 
Verma et al. [58] investigated microfluidization for nanosuspension preparation using a quality by 
design approach. The milling time, microfluidization pressure, stabilizer type, processing 
temperature and stabilizer concentration were the critical parameters affecting the formation of 
indomethacin nanocrystals. Xiong et al. [59] investigated the effects of production parameters, such 
as pressure, cycle numbers and crushing principles, on the mean particle size and polydispersity of 
nanosuspensions. The results showed that the cavitation forces produced from piston-gap 
homogenizers are more powerful and suitable crushing force to prepare the nanocrystals than the 
shear forces in the Microfluidizer processor. The increased pressure leads to smaller and 
homogenous particles. Until now, microfluidization has been popular in the preparation of 
emulsions, liposomes and microcapsules, rather than in the preparation of crystalline drug 
nanosuspensions. 
2.2.2.3 Combination techniques 
Combination of multiple techniques can overcome the shortages of each single technique. Baxter 
International Inc. (Deerfield, IL) invented a combination technology called NANOEDGE, which is 
precipitation followed by a second high energy step [60]. The second energy-addition step avoids 
further crystal growth and aggregation after precipitation and converts the amorphous and semi-
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unstable crystalline form arising from precipitation process to the crystalline form. Moreover, the 
subsequent energy-addition step becomes quicker and more efficient since the crystals are friable 
after the first step. The precipitation-high pressure homogenization was studied in the preparation of 
10-hydroxycamptothecin nanosuspensions [61] and nitrendipine nanocrystals [62]. They found out 
that the first size-controlling step using microprecipitation decreases the energy required and made 
the homogenization process easier. And the homogenization process promoted an annealing effect 
and helped the surfactant to adsorb onto the nanocrystal surface, which increased the stability of 
nanosuspensions. Other combination method, such as melt emulsification - high pressure 
homogenisation, were used to prepare orlistat nanosuspensions [63].  
SmartCrystal® technology, which is considered as a second generation technology of 
nanocrystals, is a series of combination technologies rather than only one technology. 
SmartCrystal® technology combines the pre-treatment and subsequent main treatment (high 
pressure homogenization, HPH), and includes spray drying-HPH, precipitation-HPH, 
lyophilization-HPH and pearl milling-HPH. These combination technologies generate faster 
production processes, smaller nanocrystals (lower than 100 nm) and improved physical stabilities 
[64, 65]. 
2.2.3 Stability of nanosuspensions  
Stability is a very important property for nanosuspensions. Nanoparticles can for example 
agglomerate, aggregate or sinter during the production or storage. Agglomerates are clusters of 
primary particles held together by weak physical interactions. Aggregation forms stronger particle 
clusters and it is often irreversible process. In sintering, individual particles are merged irreversibly 
to larger particles. Increased particle size can change the apparent saturation solubility and 
dissolution rate, and consequently change the blood plasma concentration and bioavailability for 
oral drug delivery; change the tissue distribution or cause the vascular blockage for intravenous 
injection. The decomposition/ degradation of the drug can cause the loss of potency of the drug and 
even generate undesirable and toxic chemical agents.  
In top-down techniques, a large number of newly formed surfaces with high surface energy tend 
to agglomerate/aggregate to reduce the Gibbs free energy in the system. In bottom-up techniques, 
nucleation and growth in supersaturated solution occur spontaneously with a decrease in free 
energy. These aggregation and growth behaviors related to the change of free energy are causing 
thermodynamic instability of colloidal systems. 
At the same time, nanoparticles are subject to kinetic instability in colloidal particle systems. 
There are various interaction forces between the nanoparticles. Russians Deryagin and Landau and 
the Dutch scientists Verwey and Overbeek considered the electrostatic repulsion and van der Waals 
attraction as two main forces in colloidal dispersions. Their theory looks at the balance between 
these  two opposing  forces,  known as  the  DLVO theory  of  colloid  stability.  The  energy  curves  of  
van der Waals attraction (VA), electrostatic repulsion (VR) and total (Vtotal = VA+VR) plotted against 
the distance of two spherical particles (H) are shown in Fig.3. The maximum and minimum energy 
states are showed in the curve of total energy. Van der Waals force promotes aggregation of 
particles, while potential existing on the charged particle surface expels the particles by repulsive 
inter-particle forces. The primary maximum state creates an energy barrier for aggregation, 
providing the stability of charged colloidal particles. The larger the barrier, the longer the system 
will  remain  stable.  If  the  primary  maximum  is  too  small,  the  particles  tend  to  agglomerate,  
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aggregate and sinter depending on the depth of primary minimum. The depth of the secondary 
minimum is important in determining the stability of a hydrophobic dispersion. As we know, 
particles tend to aggregate spontaneously by thermodynamic drive to decrease free energy. If the 
secondary minimum is smaller than the thermal energy, the particles will repel each other and keep 













     
     
Figure 3 The curves of van der Waals attraction, electrostatic repulsion and total potential energy against 
distance of surface separation (H) for interaction between two particles. 
Besides van der Waals attraction and electrostatic repulsion, there are many other non-DLVO 
surface forces that control the colloidal kinetic stability, such as hydrophobic forces, hydration 
forces, oscillatory structural forces, neutral polymer-mediated surface forces [68]. For hydration 
forces, the particle surface groups bind with water molecules and become solvated. Two hydrated 
surfaces generate the repulsive hydration forces. In an aqueous medium, hydrophobic interactions 
between hydrophobes are spontaneous. Hydrophobic forces are much stronger than the van der 
Waals attraction forces and hydrogen bonds [68]. Depending on the particle size, size deviation and 
surface properties, the importance of different forces can vary. The situation is further complicated, 
when nanosuspensions are dried for formulation purposes. In nanocrystalline systems the balance 
between attractive and repulsive forces are adjusted by adding stabilizers on the particle surfaces.  
2.2.3.1 Stabilizers 
Stabilizer plays a very important role in particle size reduction and stability of nanosuspensions. 
Stabilizers can spontaneously adsorb on and cover the newly formed particle surface to (a) decrease 
the free energy of system and interfacial (surface) tension of particles; (b) form a dense hydrophilic 
layer around hydrophobic particles, provide steric hindrance and steep repulsions between the 
particles (steric stabilization); (c) charge the particle surface if the stabilizer has ionizable groups, 
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electrostatic stabilization (Fig. 4). The stabilizers, including polymers, surfactants and their 
















Figure  4 The mechanism of nanocrystal stabilization during particle reduction (1): steric stabilization (2), 
and electrostatic stabilization (3). 
Homopolymers used as stabilizers always contain hydrophilic backbone chains, such as 
polyvidone (PVP), polyvinyl alcohol (PVA), hydroxypropylcellulose (HPC), 
hydroxypropylmethylcellulose (HPMC) and methylcellulose (MC). These polymers can adsorb on 
the particle surface by hydrogen bonds to form a hydrodynamic boundary layer. Douroumis et al. 
[69] screened various stabilizing agents for carbamazepine using the cosolvent technique. Cellulose 
ethers (HPMC and MC) contain a high degree of substitution as methoxy or hydroxypropoxy 
groups, which can form hydrogen bonds with the drug and inhibit the crystal growth. The stability 
of the nanosuspensions is dependent on the degree of substitution. PVP has only one hydrogen 
bonding carbonyl group per molecule unit, showing a weak crystal inhibition because of less 
favorable drug-polymer association. Opposite to the above results, Choi et al. [70] found out that 
hydrophobic drug surfaces without polar functional groups are ideal for HPC and PVP to physically  
adsorb and produce steric stabilization, since the hydrogen bonding between polymer and drug 
tends to interfere the stabilization activity of polymers. 
Amphiphilic block/graft polymers comprising of hydrophobic and hydrophilic chains are more 
promising stabilizers compared to homopolymers. The hydrophobic segments adsorb on the 
surfaces of the drug crystals by hydrophobic interactions, while the hydrophilic segments cover the 
drug particles and stick out into the solution, giving the steric hindrance and preventing particle 
aggregation and growth. The most common amphiphilic polymers are poloxamer 407 (F127) and 
poloxamer 188 (F68). Several factors can affect the nanosuspension particle size and stability, such 
as hydrophilic/hydrophobic ratio, molecular weight, functional groups and morphology of 
polymers. Lee et al. [71] synthesized a series of amphiphilic copolymers with the same hydrophobic 






naproxen after milling indicated that an effective stabilization performance of copolymers required 
the hydrophobic moiety content to be higher than 15%. The hydrophobic moiety of copolymer is a 
driving force for polymer diffusion and absorption onto the drug particles. The higher the 
hydrophobicity of polymer, the faster diffusion, stronger absorption and longer time for desorption 
of polymer are obtained. Hydrophilic polymers (such as PVP) are worse stabilizers for poorly 
soluble drugs compared to the amphiphilic polymers and surfactants, because they lack the 
thermodynamic driving force to adsorb on the hydrophobic drugs [72]. In another publication of 
Lee et al. [73], a series of amino acid copolymers as stabilizers were studied on seven model drugs 
during the wet milling. When 100% hydrophilic stabilizer polylysine was used, nano-sized particles 
could still be successfully obtained since the polylysine has a strong hydrogen bonding capability. 
The authors concluded that the existence of special interactions between the drug and polymer are 
more important than hydrophobic interactions in nanomilling. Similar to amphiphilic polymers, a 
surfactant contains a hydrophilic head and hydrophobic tail(s). The surfactants are smaller 
molecules compared to polymers, and have faster diffusion and adsorption kinetics on the particle 
surface [72]. Furthermore, a surfactant, like amphiphilic polymers, can reduce the interfacial tension 
and increase the wettability of nanoparticles. 
Ionic polymer or surfactant adsorbed on particle surfaces leads to higher energy barrier by 
electrostatic repulsive forces and results in good stability. For example, sodium dodecyl sulfate 
(SDS) attaches to the particles by hydrocarbon tails, and the anionic sulfate groups stay outside 
(Fig.4). A polymer such as poly (lactic-co-glycolic acid) (PLGA) can shift the particle surface 
charge to negative values because of the carboxylic acid groups in the polymer structure [74]. 
Chitosan has a number of free amine groups and can therefore form a positively charged layer on 
the surface of particles [75]. Dai et al. [76] used the ionic interaction between sulfate groups of 
carrageenan (stabilizer) and oppositely charged drugs to prepare stable nanosuspensions by wet 
milling. Dextran sulfate having negative charges, acts as a stabilizer during wet milling and is also 
effective for producing nanosized suspensions. 
Combinations of polymer-surfactant or polymer-polymer are considered for synergistic effects 
for nanosuspension preparation and stability. Bilgili et al. [77] checked the role of polymers/ 
surfactants on breakage rate of the griseofulvin suspensions using the wet media milling. The 
narrowest particle size distribution and smallest particle size of nanosuspensions were found at the 
combination of HPC-SDS as stabilizers compared to using HPC alone and SDS alone as stabilizer. 
Ryde et al. [78] invented the combination usage of at least one polymeric stabilizer and anionic 
surfactant dioctyl sodium sulfosuccinate in nanosuspension production and subsequently drying 
process. The solid dose nanoparticulate compositions exhibited superior redispersibility after 
administration to mammals. Lee et al. [79] studied the particle sizes of 11 different drugs after 
nanocomminution in the presence of polymeric stabilizer and ionic surfactant (anionic surfactant 
SDS and cationic surfactant benzethonium chloride). The results indicated that the addition of 
surfactant is not always beneficial for particle size reduction. Surfactant addition might hinder the 
interactions between the polymer and drugs and increase the particle size for some drugs. 
Choice of stabilizer type and concentration is critically important for particle size reduction and 
stabilization of the formulation. Every drug compound has typically its own optimal stabilizer. The 
stabilizer amount is usually in the range of 1:20 to 20:1 (stabilizer weight: drug weight) [80]. The 
effect of stabilizer concentration is described in detail in the physical stability part. Having a surface 
tension  value  of  the  polymer  close  to  the  one  of  drug  is  beneficial  for  the  size  reduction.  High  
viscosity of polymers have inherent disadvantages, such as decreasing the diffusion velocity of 
polymer molecules, slowing down the movement of milling pearls and hindering the energy 
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delivery, and delaying the preparation procedure [81]. A stabilizer with a low melting point makes 
problems in manufacturing process with the high temperature, such as spray drying [82]. The 
toxicity of stabilizers should be considers in different drug delivery routes. For instance, cationic 
surfactants lead to hemolysis in i.v. injection and anionic surfactants are toxic for oral application. 
Commercialized stabilizers shorten the approval time and decrease the risk of new formulation 
application rejection, e.g. surfactants of lecithin and Span 85® have been approved for pulmonary 
inhalation products [83]. Meanwhile some new synthesized polymers or natural stabilizers have 
been found [84]. Furthermore, stabilizers have other functions in formulations except the 
stabilization. SDS was reported to open tight junctions and enhance the transport of molecules 
across epithelial barriers, consequently increasing the drug passage through gastrointestinal 
membrane and blood-brain barrier (BBB) [85]. Polysorbate 80 can also facilitate the drug to 
overcome the BBB [86]. The common stabilizers used in nanocrystals are listed in Table 4. 
Table  4 Examples of stabilizers for nanosuspension preparation used in media milling (MM) or high 
pressure homogenization (HPH) process. 
 Stabilizer API Method Ref. 







PEG BDD, paclitaxel MM [79] 
 PVP naproxen, anthracene MM [70] 
 indomethacin HPH [50] 
 glimepiride, BDD, digitoxin, naproxen, paclitaxel MM [79] 
 halofantrine MM [89] 
 HPC ibuprofen, glimepiride, BDD, digitoxin, naproxen, 
paclitaxel,  nifedipin, itraconazole, 
MM [79] 
 naproxen, ibuprofen, nifedipin, anthracene, 
itraconazole 
MM [70] 
 HPMC nabumetone, halofantrine MM [89] 
 ibuprofen HPH [90] 
 nitrendipine HPH [51] 
 indomethacin HPH [58] 
 Inutec SP1 hesperetin HPH [91] 
Tyloxapol budesonide HPH [92] 
brinzolamide MM [93] 
Copolymer Poloxamer 
188 
glimepiride, BDD, digitoxin, naproxen, paclitaxel, 
nifedipin, itraconazole, hydrocortisone acetate, 
prednisolone acetate 
MM [79] 
 piroxicam HPH [52] 




 hydrocortisone, prednisolone, dexamethasone HPH [99] 
 Poloxamer 
407 
glimepiride, BDD, digitoxin, naproxen, paclitaxel, 
itraconazole 
HPH [79] 
 danazol, itraconazole HPH [100] 
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 etoposide, paclitaxel MM [101] 
 simvastatin HPH [50] 
 Poloxamer 
338 
probucol MM [45] 
Non-ionic 
surfactant 
Tween 80 celecoxib HPH [82] 
hesperetin  HPH [91] 
ascorbyl palmitate HPH [102] 
rutin HPH [87] 
 PX-18 HPH [54] 
 Tween 20 folic acid HPH [53] 
 Vitamin E 
TPGS 
cinnarizine, griseofulvin, indomethacin, itraconazole, 
loviride, mebendazole, naproxen, phenylbutazone, 
phenytoin 
MM [103] 
 fenofibrate HPH [104] 
 probucol MM [45] 
 Plantacare 
2000 
hesperetin HPH [91] 
 lutein HPH [105] 
 Gelucire probucol MM [45] 
  itraconazole, febantel  MM [106] 




spironolactone HPH [107] 
Cationic  Benzethoni-
um chloride 
glimepiride, nifedipin, hydrocortisone acetate MM [79] 
Zwitterionic Lecithin buparvaquone HPH [83] 
2.2.3.2 Physical stability 
Because of thermodynamic and kinetic instability, drug nanoparticles in the colloidal system tend to 
agglomerate, aggregate and sediment, which appears in the form of particle size growth and phase 
separation. The steric or ionic barriers provided by stabilizer are the main forces to prevent the drug 
nanoparticles from getting into contact with each other. The higher the barrier energy, the more 
stable nanosuspensions are obtained. For an electrostatically stabilized nanosuspension, a minimum 
zeta potential of ±30 mV is needed. For a combined electrostatically and sterically stabilized 
nanosuspensions, a minimum zeta potential of  ±20 mV is required [108].  
Ostwald ripening is another important factor influencing the physical stability of 
nanosuspensions. Ostwald ripening is caused by the differences in dissolution pressure/apparent 
saturation solubility between small and large particles. The smaller particles have a higher solubility 
compared to the larger particles. Smaller particles are dissolved faster and free molecules diffuse to 
the larger particles possessing lower drug solubility. A supersaturated environment around the 
larger particles is formed, which consequently results in the growth of larger particles. To simplify, 
Ostwald ripening is the process of shrinking of smaller particles and growth of larger particles. 
There are two preconditions for Ostwald ripening: (i) the particle size in nanosuspensions should 
not be uniform, i.e. the nanosuspension should be polydisperse and (ii) the dispersed phase (drug 
nanoparticles) should have finite solubility in the dispersion medium [109]. Pharmaceutical drug 
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nanoparticles mostly fit these two requirements of Ostwald ripening. Therefore, Ostwald ripening 
finally leads to the larger average size of nanosuspensions during the storage.  
Given the preconditions of Ostwald ripening, homogenous nanosuspensions can effectively 
decrease the chance of Ostwald ripening; the drug nanocrystals having the lower solubility (e.g. 
drug crystals) should be more stable than the ones having the higher solubility (e.g. amorphous drug 
nanosuspensions). Introducing a second component as an inhibitor, which is miscible with the drug 
compound but essentially insoluble in the continuous phase, to the nanosuspensions can inhibit the 
Ostwald ripening. For example, the addition of Miglyol has been shown to effectively inhibit the 
Ostwald ripening of felodipine, nifedipine and bicalutamide amorphous nanosuspensions [110].  
The concentration of the stabilizer has a pronounced effect on Ostwald ripening. A low 
concentration of stabilizer could result in an insufficiently/partially covered particle surface, which 
cannot impart the repulsive forces to prevent particle aggregation. Meanwhile, more than one drug 
particle can adsorb on the same polymer chain, which leads to the polymer bridging attraction and 
thereby to aggregation [111]. A sufficiently high concentration of stabilizer provides a thicker 
coating layer on the nanocrystals and better long-term stability [112]. However, the high 
concentration of surfactant/polymer also can enhance the particle growth. Deng et al. [113] 
investigated the effect of stabilizer F127 concentration in the stability of paclitaxel nanocrystals. 
When the stabilizer concentration was below its critical micelle concentration (CMC), smaller and 
stable paclitaxel nanocrystals were formed because of the high affinity of F127 on drug particles. 
When the amount of stabilizer was increased above the CMC, the competition between polymer-
polymer and polymer-particles occurred and the polymer-polymer interaction to form micelles was 
stronger than polymer-particles, which worsened the stability of nanocrystals. The particles tended 
to aggregate in the higher F127 concentration. In addition, the micelle formation improves the drug 
solubility and thereby enhances the particle growth by the Ostwald ripening process [28]. 
Temperature is another important influencing factor in the physical stability of nanosuspensions. 
Higher temperature can increase the saturation solubility of drug, hydrophobic interactions between 
particles and the dehydration of polymer. Therefore, the nanoparticles tend to aggregate or grow in 
storage conditions with higher temperature [109, 113]. Polymorphic transitions during the storage 
should be considered as another instability factor.  
Energy-addition, such as ultrasonication after the precipitation, and HPH after the precipitation, 
can enhance the stability. Xia et al. [30] combined the precipitation-ultrasonication to prepare the 
stable nitrendipine nanosuspensions. The results showed that the particle size of non-sonicated 
nanosuspensions increased in 24 h, while the sonicated sample was stable for 6 months. Sonication 
is a kind of annealing step, which converts the thermodynamically unstable regions into a more 
stable form. The sonication reorders the surfactant molecules and prompts the surfactant absorption 
rate on the particle surface as well as disrupts the crystal agglomeration. Meanwhile, the sonication 
energy input transfers the instable polymorph form to stable crystal form and changes the crystal 
habit [29, 30]. However, if the energy input goes over a critical value, the particles will collide and 
agglomerate because of the extra kinetic energy [28, 29]. In addition, transferring the suspensions to 
dried solid state is another approach to improve the physical stability of nanosuspensions [103].  
Under the critically optimal storage conditions, nanosuspensions exhibit a long-term stability. 
The commercialized Megace® ES nanoparticle dispersion formulation of megesterol acetate shows 
a 2 year shelf life in an ambient temperature. It was reported by Merisko-Liversidge et al. [80] that 
the drug nanosuspensions prepared in their laboratory exhibited excellent physical stability for 5 
years at 5 oC, which provided the sufficient time to prepare a formulation, perform preclinical 
testing and a good shelf life. 
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2.2.3.3 Chemical stability 
Many drugs are susceptible to decomposition or degradation during manufacture, package and 
storage, depending on environmental factors, such as temperature, pH, ionic strength, humidity, 
oxygen and light [66]. Such decomposition causes a loss of potency of the drug, difficulties in 
predicting the administration dosage, changes in physical appearance of dosage form (such as 
discoloration), and can even generate the undesirable and toxic chemical agents.  
Formulating a chemical compounds into nanoparticulate compositions is a promising way to 
decrease the degradation and improve the chemical stability [114]. For a drug solution, drug 
molecules dissolve in the medium, which leads easily to degradation by oxidation or hydrolysis. For 
nanocrystals, chemical reactions take place just on the crystal surface, and the degraded outer 
monolayer can form a protecting shell to shield the inner core of crystals [115]. Besides the crystal 
structure, the stabilizer layer around the particle surface can also form a relatively closed micro-
environment to reduce the contact of the drug with the outer water environment and decrease the 
chance of degradation. In the presence of a surfactant polysorbate 80, a 7-fold increase in the 
stability of indomethacin has been reported [116]. Pu et al. [61] reported that 90% of 10-
hydroxycamptothecin (10-HCPT) in the lactone form was preserved in the nanosuspension 
formulation at physiological pH values after 24 h incubation, while less than 30% of 10-HCPT in 
the solution was left in the same conditions. An increased chemical stability of nanosuspension 
compared to solutions was also seen in other publications [96, 117]. 
Converting a drug solution or nanosuspensions to dried solid particles is another promising way 
to increase the chemical stability and decrease hydrolysis, which is the main problem for liquid 
formulations. The drying methods and advantages of nanopowders are presented in the next chapter 
(2.3.1). 
2.3 Pharmaceutical application of nanosuspensions 
Conversion of liquid nanosuspensions into solid dosage forms, such as tablets, capsules, pellets and 
granules, can improve the commercialization, allow better handling and avoid the potential physical 
instability (agglomeration and Ostwald ripening) and chemical instability (e.g. hydrolysis, 
oxidation). 
2.3.1 Solidification of nanosuspensions 
There are two different types of drying technologies to solidify nanosuspensions. First method is 
drying the nanosuspension to a powder using lyophilisation, spray drying, or oven drying, and then 
further  formulating  the  powder  into  e.g.  tablets  and  capsules  with  other  excipients,  such  as  
dispersants, disintegrates and so on. The second solidification method, including granulation and 
pelletization, is the combination of drying and shaping processes together. The nanosuspensions are 
used as a granulating liquid in the granulation process or as layering dispersion in a fluidized bed 
process [118, 119].  
During the drying process the water is removed from the nanocrystals suspensions by 
evaporation or sublimation and the motions of stabilizer chains around the nanocrystals are 
decreased because of the dehydration or possible partial crystallization. The steric repulsion 
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supplied by the stabilizer ceases and then the polymer chains adsorbed on the particles can entangle 
each other, which hinder particle separation and prompts particle aggregation. In addition, the 
contact points among nanocrystals are increased with water removal. Under mechanical stresses 
(such as crystallization of ice, the stress of freezing and dehydration) and additional thermal stresses 
occurring in the drying process, nanocrystals are subject to reversible agglomeration or irreversible 
aggregation/fusion. The agglomeration/aggregation can compromise the advantages of nanocrystals 
based on the large surface area, e.g. decreased dissolution rate, the lag time in the beginning of the 
dissolution, and unpredictable variations in bioavailability [120]. Therefore, re-dispersibility of 
dried nanopowders in the dissolution medium with a short time (a few minutes) is an important 
standard to evaluate the drying step.  
The parameters of the drying procedure, the properties of drug compounds, the choice of 
dispersed matrix and stabilizer can affect the nanocrystal re-dispersibility. In freeze drying process, 
fast freezing and low API concentration are beneficial for re-dispersibility [121]. In spray drying 
process, high gas flow rate and feed temperature lead to formation of donut shaped particles [122]. 
Spray drying at high inlet temperature causes powders with higher lag time as well as lower 
dissolution rates [120]. Eerdenbrugh et al. [103] showed that regardless of the drying methods or 
other properties of drug compounds, such as molecular weight, melting point, solubility and 
density, the hydrophobicity of drug surface, which in general corresponds to log P values (partition 
coefficient) of the drug, is a key parameter for nanocrystal re-dispersibility. More hydrophobic 
compounds resulted in harder–to–disintegrate agglomeration. Chaubal et al. [120] showed that 
using a charged surfactant as a stabilizer and sugar as excipient can effectively prevent irreversible 
aggregation compared to non-charged polymeric surfactants and sugars. Excipients are usually 
added during the freeze drying process to protect the product from freezing stress (cryoprotectant) 
or drying stress (lyoprotectant) [123]. The commonly used excipients include water-soluble sugars 
such as mannitol [124, 125], sucrose [126], lactose [125], trehalose [102, 127] and water-insoluble 
microcrystalline cellulose (MCC) as a matrix-former [128] to protect the nanocrystals from 
aggregation. The results showed that the reconstituted nanocrystals dried with excipients had 
smaller mean particle size than the ones dried without added lyoprotectant. The preferable amount 
of cryoprotectant used is about 2%-25%, based on the total weight of the nanoparticulate 
suspension [129]. Sometimes, dried powders without any excipients exhibit good re-dispersibility 
since stabilizers used in nanocrystal production act lyo/cryprotectant in a certain extent.  
2.3.2 Drug delivery routes 
2.3.2.1 Oral delivery 
Oral dosage forms are usually the first choice for drug delivery due to their convenience, good 
patient compliance and low production costs. The efficacy of the drug by oral administration is 
dependent on the solubility and absorption in the gastrointestinal tract. Poor solubility and low 
dissolution  rate  of  the  drug  in  human  GI  lumen  can  lead  to  a  large  amount  of  undissolved  drug  
escaping from the adsorption window and therefore poor bioavailability. To reach the 
therapeutically relevant drug concentrations, a high drug dose is required, which can cause 
undesirable  side  effects  to  the  normal  tissue,  poor  patient  compliance  and  costly  therapy.  The  
nanocrystals can effectively improve bioavailability. Using nanocrystals can lead to e.g. higher 
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maximum  peak  concentration  of  the  drug  in  plasma  (Cmax) and faster onset of action, faster 
dissolution in the narrow absorption window, reduced fast/fed variation, improved dose 
proportionality and reduced inter-subject variability, which are described in detail below. For oral 
administration of nanocrystals, they can be formulated into tablets, grain-filled capsules, 
suspension-filled capsules, pellets and oral suspensions.  
The Cmax and oral bioavailability of the drug can be improved by the particle size reduction. 
There are two main reasons. Firstly, decreasing the particle size increases the surface area-to-
volume ratio. According to the Noyes–Whitney and Ostwald–Freundlich’s equations, the 
dissolution velocity and apparent saturation solubility are increased. The high drug concentration 
gradient between the gastrointestinal contents and blood enhances the drug absorption. Secondly, 
the bioadhesion property of nanoparticles to gastrointestinal mucosa prolongs the retention time, 
decreases diffusion distance, and increases local drug concentrations. Xia et al. [25] prepared five 
different particle sizes of nitrendipine nanosuspensions using precipitation-ultrasonication method 
and administrated the nanosuspensions to rats orally. The dissolution testing and simulated results 
having good agreements showed that the simulated dissolution rate at T50% (50% dissolution time) 
of nitrendipine nanocrystals with particle sizes of 200 nm, 620 nm, 2.7 µm, 4.1 µm and 20.2 µm 
were calculated to be 5.1×104-, 1×104-, 237-, 64- and 11-fold greater than that of the raw crystals, 
respectively. The in vivo testing showed that the absolute bioavailability of five samples were 61.4, 
51.5, 29.4, 26.7 and 24.7 %, respectively. The absolute bioavailability of raw crystals was only 
9.9%. In addition, a good linear relationship was observed between the Log (T50%) and the absolute 
bioavailability. Liversidge et al. [130] compared the pharmacokinetic parameters between 
conventional suspensions (particle size of 10 µm) and nanoparticle dispersion (169 nm) prepared by 
a ball milling process. The results showed that the Cmax and  oral  absolute  bioavailability  of  
conventional suspensions of danazol in dogs were 0.2 µg/ml and 5.1%, while for nanosuspensions 
they were 3.94 µg/ml and 82.3%. Quan et al. [62] prepared nitrendipine nanosuspensions using 
precipitation-homogenization process and converted the nanosuspensions to a solid form using 
spray drying. The results of in vivo testing indicated that the Cmax of the nanocrystals was about 15-
fold and 10-fold greater than that of physical mixture and commercial tablet, respectively. 
Meanwhile, The AUC (Area under the plasma concentration time curve)  of  the  nanocrystals  was  
about 41-fold and 10-fold greater than that of physical mixture and commercial tablet, respectively. 
Improved bioavailability with nanocrystal formulations can be found in a number of other 
references as well [131]. The improved bioavailability leads to a decrease in the administrated dose 
and times, decreased side effect and is good for patient convenience.  
A faster onset of action (shorter Tmax (The  time  that  Cmax happens)) can be obtained by 
nanoformulations compared to the microparticles. Li et al. [98] prepared revaprazan hydrochloride 
nanosuspensions using high pressure homogenization and researched the in vitro/in vivo evaluations 
of drug nanosuspension (particle size of 562 nm), microsuspension (1.5 µm) and coarse suspension 
(2 µm). The Tmax of nano-, micro- and coarse suspensions were 45, 360 and 230 min, respectively. 
Ravichanran [132] compared 3 kinds of lyophilized albendazole nanosuspensions formulations with 
a slightly varied particle sizes but very much lower size than the control (an unmilled albendazole 
sample). The Tmax of  sample-control  was  5.95  h,  but  the  Tmax of the three nanoformulations were 
4.63, 3.80 and 3.67 h, respectively.  
Food affects the drug absorption and consequently alters the pharmacokinetic and 
pharmacodynamic profiles of drugs [133]. Nanoformulations can effectively reduce the fed/fasted 
state  variability  since  the  similar  rapid  dissolution  was  obtained  in  fasted/fed  conditions  and  the  
dissolution/absorption become less dependent on the diet and physiological state [134]. Jinno et al. 
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[135] investigated the absolute bioavailability of wet-milled cilostazol nanocrystals tablet in beagle 
dogs in fasted and fed conditions. The commercial tablet provided 5% bioavailability of cilostazol 
in the fasted state and 20% in the fed state, while wet milled nanocrystals in a tablet formulation 
exhibited 64% bioavailability in the fasted state and 69% in the fed state. The cilostazol 
nanocrystals not only remarkably enhanced the bioavailability, but also eliminated the food effect 
on absorption. Shono et al. [136] used an in silico simulation technology to forecast in vivo oral 
absorption of micronized and nanosized aprepitant formulations in the pre- and post- prandial states. 
The simulated plasma profiles generated for a dose of 125 mg aprepitant having various particle 
sizes demonstrated that the ratio of Cmax and AUC in fed/fasted states decreased with decreasing 
particle size, meaning that the food effect on absorption of aprepitant was diminished with the 
decreasing particle size. The simulated results were in good agreement with the available in vivo 
data in humans. 
The gastric irritancy can be eliminated with the decreasing particle size of the drugs. Liversidge 
et al. [46] reduced the particle size of naproxen material from 20 µm to 270 nm using a roller mill. 
The results of stomach irritations indicated that the milled naproxen formulation had significantly 
lower irritation scores than the unmilled naproxen. No significant difference was found in stomach 
irritation following administration of nanoparticle naproxen comparing the oral and intravenous 
routes.  
There are other effects of nanoformulations on drug pharmacokinetics and therapeutic efficacy. 
The fast dissolution can overcome the challenges of a narrow absorption window [134], improve 
dose proportionality and reduce inter-subject variability [65]. The bioadhesion property of 
nanoparticles can not only improve the bioavailability, but also reduce the variability of absorption 
and can be used for targeted drug delivery in the GIT [24, 137]. The efficiency of mucoadhesion 
process depends on the surface properties of the particles and the polymer [20]. A controlled release 
pellet formulation was developed using the spray dried nanocrystal nanosuspensions dispersed in 
the hydrophobic matrix pellets [138]. 
2.3.2.2 Ophthalmic delivery 
There are three main routes for drug delivery to the eye: topical, systemic and intraocular injection. 
Nearly  90%  of  ophthalmic  products  on  the  market  are  in  the  form  of  eye  drops  for  topical  
administration, including solutions, ointments and suspensions, which mainly target the anterior 
segment eye diseases [139].  
Ocular drug delivery has remained as one of the most challenging research topics, because of 
the unique structure and effective removal mechanisms of the eye (keep the ocular surface free from 
foreign substances). The fate of instilled dose can be seen in Fig.5. Firstly, The cul-de-sac of the eye 
normally holds about 7-9 µl of tear fluid but can retain up to 20-30 µl of liquid if care is taken not to 
blink [140]. However, the volume of a drop delivered from normal commercial eye dropper is 
approximately 25-56 µl (average 39 µl) [141]. The excess volume of instillation into the lower cul-
de-sac will be spilled out of the eye. Also, the drops can be drained from the eye by various 
mechanisms, such as blink reflex and rapid tear secretion after irritation. The human tear flow rate 
is 1 µl/min under resting conditions [142]. It was reported that an eye-drop is often eliminated 
quickly  within  5-6  minutes  after  administration  [142]  and  has  a  short  residence  time  of  about  2  
minutes in the tear film [143]. Secondly, physiological factors can affect the ocular delivery of 
topical drugs, such as protein binding and drug metabolism by the enzymes in tear fluid. Thirdly, 
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the special structure of the eye acts as a physiological barrier. The cornea comprising of epithelium, 
stroma and endothelium, acts as a protective barrier to prevent the drug absorption into the eye 
[144]. Finally, the drops can go through the nasolacrimal duct into the nasal cavity and then down 
to the throat and gastrointestinal tract and ultimately enter the systemic absorption. The absorption 
of drops by conjunctiva and sclera will also enter the blood circulation. More than 75% of applied 
ophthalmic solution is lost or absorbed systemically by nasolachrymal drainage and conjunctiva 
[145], which cause undesirable systemic side effects, e.g. timolol may cause severe (up to patient 
death) systemic side effects in the form of reduced heart rate and blood pressure [146]. Because of 
the rapid precorneal drug elimination and corneal epithelial barrier, less than 5% of the drug dose 














Figure 5 Fate of ophthalmic drug delivery systems (modified after reference [144]). 
The poor ocular bioavailability of eye drops leads to problems in drug delivery. A large 
ophthalmic dose is needed to reach the effective therapeutic concentration of the drug, which results 
in poor compliance and, potentially, serious systemic toxicity. Another problem for ophthalmic 
delivery is a short duration of action for some drugs. It was reported that the duration of lowering of 
intraocular pressure caused by pilocarpine lasted only about 3 hours. As a consequence, a high 
administration frequency of 3-6 times/day is required which results in undesirable side effects such 
as myopia and miosis [148].  
To overcome the disadvantage of conventional eye drops, novel ocular drug delivery systems 
have been developed in the past several decades, such as prodrugs, cyclodextrins, microemulsions 
[149, 150] colloidal drug delivery systems (nanoparticles [151], nanosuspensions, micelles [152] 
and liposomes), intraocular implants [153], soft contact lenses [154, 155], hydrogel systems, ocular 
iontophoresis. The basic ideas of these novel drug delivery systems are prolonging the precorneal 
residence time, enhancing corneal drug penetration and achieving a sustained drug release to finally 
improve the duration of action and bioavailability. To prolong the precorneal drug residence time, 
viscosity enhancers such as viscosity-increasing polymers [156],  mucoadhesive agents [157], in 
situ gels and soft contact lenses can be used. Drug carriers with positively charged surfaces are 
preferentially captured at the cornea, since corneal surface has a negative charge [158]. To enhance 
the drug corneal penetration, penetration enhancers, such as cetylpyridinium chloride, Tween 20, 
Brij® 35, among others, have been used to increase the permeability of the corneal epithelial 
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membrane [159]. The formation of prodrug obtained by chemical modification of the active agents 
is another approach to enhance the partitioning in corneal. For example, changing the epinephrine 
(EPI) to a more lipophilic compound dipivalyl epinephrine (DPE), the partition coefficients of DPE 
is 100-600 times higher than that of EPI [160],  since the epithelium of the cornea are rich in lipid 
content. Transporter-targeted prodrug is another way to improve the absorption and bioavailability 
[161]. For sustained drug release, gels, nanoparticle-loaded contact lenses and intraocular implants 
have been widely researched [153, 162, 163]. 
With the development of the nanocrystal technique, nanosuspensions have been researched and 
formulated in the form of eye drops. Drugs with poor solubility in aqueous or organic solvent can 
be transferred into nanosuspensions with a high dissolution rate and apparent saturation solubility, 
which supply a higher concentration gradient in precornea and a higher drug flux through the 
cornea. The nano-scale particle size and a narrow size range ensure low irritation of the eye. Particle 
size  in  an  eye  drop  must  be  less  than  10  µm  to  avoid  the  irritation  of  the  eye  surface  [156].  
Moreover, nanosuspensions are more comfortable for the eye since less drug is in the solution 
[164]. Nanoparticles show a higher bioadhesion [41, 165] which prolongs the residence time of 
nanoparticles in the eye and thus provide a longer time for the dissolution in tears. On the other 
hand, (nano-sized) particles tend to retain in the cul-de-sac [166] and act as a reservoir for sustained 
release of the drug, which can extend the duration of drug action and decrease the administration 
frequency [36]. The importance of particle size in ophthalmic bioavailability was investigated [167] 
and nanosuspensions were shown to improve the ophthalmic bioavailability [168]. In addition, the 
mild pH range of 3.5-9 (prefer as close to physiological pH as possible) and simple formulation of 
nanosuspensions avoid the pH-induced or excipient-induced irritation, lacrimation and discomfort. 
Ali et al. [36] prepared hydrocortisone nanosuspensions using microfluidic nanoprecipitation 
and wet milling for ophthalmic delivery. The results of tests in vivo indicated that the 
nanosuspensions had an onset of drug action as fast as the drug solution, but a longer duration of 
drug action and higher AUC value. Kassem et al. [99] reported that nanosuspensions allowed lower 
doses and less frequent instillation in ophthalmic drug delivery, since the extended duration of drug 
action and higher bioavailability were found in nanosuspensions compared to the solution. 
Moreover, the maximum percentage of increase in intraocular pressure (IOPmax) is dependent on the 
particle size of nanosuspension, e.g. dexamethasone micro- and nanosuspensions with the particle 
sizes of 930 nm, 2.46 µm and 4.89 µm exhibited the significantly different IOPmax values 24.97, 
19.95 and 17.35%, respectively. 
The drug of particular interest in this thesis was brinzolamide. It was first marketed in 1998 with 
the trade name Azopt® by Alcon Inc. using the nanocrystal technique for the treatment of open-
angle glaucoma and ocular hypertension [169]. Many comparisons of IOP-lowering efficacy, safety 
and tolerability were done between brinzolamide 1.0% suspension (Azopt®) and dorzolamide 2.0% 
solution (Trusopt®) [169, 170]. The data [171] collected from patients showed that brinzolamide 
1.0% (dosed two times a day) and dorzolamide 2.0% (dosed three times a day) equaled each other 
in IOP-lowering efficacy and brinzolamide was significantly more comfortable than dorzolamide, 
which generated ocular burning and irritation. 
2.3.2.3 Parenteral/Intravenous administration 
Water insolubility of the drug compound has always been a challenge in parenteral administration. 
To solubilize the drug, surfactants (e.g. polysorbates), cosolvents (e.g. ethanol, glycerin and 
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propylene glycol), emulsions, nonaqueous vehicles (e.g. sesame oil) and cyclodextrin inclusion 
complexes can be used [172]. However, large quantities of solubilizing excipients are associated 
with undesirable adverse effects. For example, Cremophor® EL (polyethoxylated castor oil) in 
Taxol® is added to enhance the solubility of anti-cancer drug paclitaxel. The surfactant of 
Cremophor EL causes hypersensitivity reactions in certain patients [173]. Adjusting the pH of 
dissolved medium to solubilize the ionic API can lead to a local tissue irritation, necrosis and 
possible chemical instability of the drug. Compared to the drug solutions, nanocrystals are a smart 
approach exhibiting many advantages for i.v. administration. The small amount of excipients causes 
only limited intravenous irritation [59] and thus they are well tolerated at higher doses [101, 174]. 
The high drug loading makes the drug administration possible with a high dose but relatively small 
injection volume.  
Drug nanoparticles also show potential for targeted drug delivery, sustained release and 
improved drug efficacy. Once nanosuspensions are intravenously injected, the fate of nanocrystals 
is controlled by the particle size, surface properties (such as zeta potential, hydrophilic/hydrophobic 
ratio) and particle shape. Smaller particles will be rapidly dissolved in blood stream and the 
pharmacokinetics are similar to the drug solution, while larger particles with lower dissolution 
velocity will circulate in bloodstream, much like with any other particulate drug carriers (e.g. 
polymeric nanoparticles) [175, 176]. Particles will be taken up by mononuclear phagocyte system 
(MPS) as foreign matter, typically within 5 min [177] to a few hours [178] depending on the 
particle size and composition. This clearance process can be considered as a passive targeting to 
macrophages or tissues abundant in macrophages, such as liver, spleen and lungs [179]. Meanwhile, 
after the uptake of phagocytic cells of MPS, drug molecules can be dissolved in phagolysosomes, 
released from phagocytic cell and then enter the blood circulation again. This phenomenon 
maintains the drug blood concentration for a longer duration [97].  
On the other hand, nanocrystals coated with hydrophilic layers and neutral zeta potential 
surfaces can reduce the opsonizing effect, avoid clearance by MPS and obtain a long circulation 
time in blood (stealth property), which provide efficient delivery time of nanocrystals to the target 
tissue [180]. The nanoparticles can be passively targeted and accumulated into solid tumor because 
of the enhanced permeability and retention (EPR) effect in tumor site [181, 182]. Active targeting 
can be achieved by modifying nanocrystal surfaces with targeting molecules, such as antibody, 
peptide, small molecule ligand and oligonucleotide [183]. Shegokar et al. [184] modified a 
nevirapine nanocrystal surface with serum albumin, dextran and polyethylene glycol to target 
macrophages. The cellular uptake studies showed decreased cellular uptake for PEGylated 
nanosuspension because of its hydrophilic protective layer. Dextran and serum albumin modified 
nanocrystals showed higher intracellular content of nevirapine compared to the un-modified 
nanocrystals due to the specific receptor-mediated macrophage endocytosis. The results of gamma 
imaging demonstrated that surface modified nanosuspensions showed comparable accumulation in 
MPS organs, especially in liver and spleen as compared to drug solution and un-modified particles 
since the modified nanocrystals with the larger particle size can be easily phagocytosed by 
macrophages. Through surface modifications of nanocrystals, drug target accumulation and 
bioavailability were enhanced, and the residence of the drug at the target site was prolonged. 
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2.3.2.4 Other delivery routes 
Pulmonary administration is a non-invasive and promising drug delivery route for the treatment of 
local lung diseases or systemic circulations for non-respiratory diseases (especially for peptides and 
proteins) since lungs have an enormous surface area, a relatively low enzymatic activity and good 
blood supply. Aerosol particle size is one of the important influencing factors for dose deposition, 
distribution  and  therapy  efficacy  within  the  lungs.  Aerosol  particles  >  10  µm  are  most  likely  
deposited  in  the  mouth  and  throat;  5-10  µm  are  mainly  deposited  in  the  upper  airways  or  
oropharyngeal region; Particles with a diameter of 1-5 µm are deposited in the small airways and 
alveolar region [185]. Currently, micron-sized inhalation powders are prepared by jet mill, which 
produces particles with a wide particle size distribution. Large particle size with a wide particle size 
distribution in inhalation formulation has certain disadvantages, such as low solubility and 
dissolution rate, unwanted deposition in pharynx and mouth rather than lungs, and quick clearance 
from the lungs by ciliary movements [186]. Nanosuspension is a versatile formulation and can be 
nebulized using commercially available nebulizers. The adhesiveness property of nanocrystals to 
mucosal surface prolongs the drug retention and release time. Nanoparticles exhibit more reliable 
delivery to the lungs since homogenous nanosuspensions contain more particles in each aerosol 
droplet than micro-suspensions and the drug content in each droplet will be more consistent [92]. 
The nanoparticles require smaller aqueous droplets generated by nebulizers, and the smaller 
droplets are important as they can carry the drug to the smaller airways, especially for young 
children [187]. With the same nebulizer (a Pari LC Jet nebulizer), ultra compressor and formulation 
volume, a significantly shorter nebulization time was found for nanobudesonide (with the size range 
of 75-300 nm) than Pulmicort Respules® (4400 nm), which improves the patient compliance [188]. 
Compared to a conventional formulation, a quick onset of action and higher therapeutic drug 
concentration of nanosuspensions were found, contributing to rapid diffusion, dissolution and 
adsorption of the nanosized nanocrystals [187-189]. Zhang et al. [189] prepared a baicalein 
nanocrystal dispersion using a combination method of precipitation and high pressure 
homogenization. The in vivo bioavailability study indicated that the pulmonary baicalein 
nanocrystals had rapid absorption and almost identical pharmacokinetic parameters to intravenous 
baicalein injection.  
Skin as the largest organ provides huge opportunities for drug delivery. The application of 
nanocrystals for dermal delivery was started in 2006 [190]. There are two cosmetic products on the 
market which contain nanocrystals. The first one contains rutin nanocrystal for age-decoder face 
cream and fluid and has been on the market since 2007 (Juvedical by Juvena). Another one contains 
hesperidin nanocrystals developed by Platinum Rare in 2009 [65]. The fast dissolution, high 
solubility, adhesiveness and sustained release properties of nanocrystals are still working in 
transdermal drug delivery system [191]. Simple formulation of nanocrystals avoiding the 
solubilization agent and organic solvent decreases the skin irritation. Venkataraman et al. [192] 
prepared silver sulfadiazine (SSD) nanosuspensions with a particle size of 367 nm using 
microprecipitation-high-pressure-homogenization technique and further formulated the 
nanosuspensions in gel matrix (nanogel) for infection in burn therapy. Bacterial inhibition studies 
showed that the bacterial inhibitory efficiency of SSD nanosuspension was as good as that of SSD 
solution against bacteria. The results of treating hot water-induced burn wounds in rats revealed that 
a nanogel containing 0.5% SSD was more effective in wound healing compared to 0.5% and 1% 
marketed cream, since the small size and large surface area of released nano silver promote closer 
interaction with bacteria.  
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2.3.3 Nanocrystals on the market 
It was reported that approximate 28 nano-drugs are on the market by 2009. These products include  
liposome based formulations, polymeric based (PEG) nanodrugs, nanocrystals and albumin-bound 
platform [193]. With the drug nanocrystals invented at the beginning of the 1990s, drug 
nanocrystals have been developed in pharmaceutical industry very fast during the last twenty years 
based on their outstanding advantages. Until now, approximately 20 nanocrystal drug products have 
been launched on the market (Table 5) and more than twenty products are currently under clinical 
trials.  
Among these nanocrystal products, almost all are prepared using the wet pearl milling 
technology. Rapamune® was marketed as a nanocrystal product in 2000 by Wyeth Pharmaceuticals. 
The drug nanocrystals are released from the tablets and from nanosuspension. No crystal 
aggregation takes place during the tablet production because of the very low drug nanocrystal 
percentage in the whole tablet (1 mg nanocrystals in 365 mg of the total tablet weight and 2 mg of 
nanocrystals in a 370 mg tablet). In comparison to the oral solution, nanocrystals have enhanced 
bioavailability (21% higher) and are user friendly. Emend® was introduced to the market in 2003. 
Aprepitant having a narrow absorption window is only absorbed in the upper gastrointestinal tract. 
The nanosized aprepitant reached improved bioavailability because of the high solubility and 
dissolution rate. Tricor® and Triglide® have the same API (fenofibrate) but are made by different 
preparation methods. The bioavailabilities of Tricor® and Triglide® are independent on the 
fed/fasted state since the dissolution rate of nanocrystals in water (fasted state) is as high as in 
fats/oils (fed state). In addition, the adhesiveness of nanocrystals to the gut wall avoids the effects of 
fed/fasted condition. For Megace ES®, the volume of a single dose is decreased by 4 times 
compared to the oral solution. Furthermore, the bioavailability variation of Megace ES® is 











Table 5 Examples of nanocrystal products on the market (modified after the reference [118]). MM and HPH 
stand for media milling and high-pressure homogenization, respectively. 
Product/Company Drug Indication Technology Route Approval 
date 
Gris-Peg®/Novartis Griseofulvin Anti-fungal Precipitation Oral 1982 
Cesamet®/Lilly Nabilone Anti-emetic Precipitation Oral 2005 
Verelan PM®/Schwarz 
Pharma 
Verapamil Anti-arrhythmia MM Oral 1998 
Azopt®/Alcon Brinzolamide Glaucoma MM Eye drops 1998 
Rapamune®/Wyeth Sirolimus Immunosuppressant MM Oral 2000 
Focalin XR®/Novartis Dexmethyl-
phenidate HCl 
Anti-psychotic MM Oral 2001 
Avinza®/King Pharm Morphine sulfate Anti-chronic pain MM Oral 2002 
Skelaxin/King Pharm Metaxolone Skeletal-muscular pain MM Oral 2002 
Ritalin LA®/Novartis Methylphenidate 
hydrochloride 
Anti-psychotic MM Oral  2002 
Herbesser®/Mitsubishi 
Tanabe Pharma 
Diltiazem Anti-angina MM Oral  2002 
ZanaflexTM/Acorda Tizanidine 
hydrochloride 
Muscle relaxant MM Oral 2002 
Emend®/Merck Aprepitant Anti-emetic MM Oral 2003 
Tricor®/Abbott Fenofibrate Hypercholesterolemia MM Oral 2004 
Megace® ES/Par 
Pharma 
Megestrol acetate Appetite stimulant MM Oral 2005 
Naprelan®/Wyeth Naproxen sodium Anti-inflammation MM Oral 2006 
Theodur®/Mitsubishi 
Tanabe Pharma 
Theophylline Bronchial dilation MM Oral 2008 
Tridlide®/Skye Pharma Fenofibrate Hypercholesterolemia HPH Oral 2005 
Invega Sustenna/J & J Paliperidone 
palmitate 
Anti-depressant HPH Injection 2009 
Zyprexa® 
RelprevvTM/Lilly 
Olanzapine Schizophrenia MM Injection 2009 
Xeplion®/J & J Paliperidone 
palmitate 
Schizophrenia MM Injection 2011 
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3 Aims of the study 
The aim of the thesis project was to optimize the preparation (wet media milling technique) and 
characterization methods of nanosuspensions for poorly water-soluble drug compounds, then 
formulate the nanosuspensions into suitable pharmaceutical dosage forms, and finally test the 
efficacy in in vivo. 
 
  The more specific aims of the present study were:  
1. In order to have the smallest particle size, most homogeneous and stable nanosuspensions, 
the most critical process parameters such as milling time, milling pearl diameter, rotational 
speed, stabilizer type and concentration were studied with model drugs (I, III, IV). 
 
2. In order to determine the importance of particle size on dissolution, the discriminating 
dissolution conditions for poorly water-soluble drug nanosuspensions using simulation and 
experimental methods were developed (III). 
 
3. To set up a “nanos-in-micros” structure for suitable pharmaceutical formulation, e.g. tablet 
or pulmonary products. This structure avoids problems in further formulation of 
nanopowders, meanwhile functionality of individual nanoparticles are remained though 
particles are micron sized (II).  
 
4. To test the efficacy of nanocrystal formulations in vivo. Brinzolamide nanosuspensions for 









4 Experimental part 
4.1 Materials 
All chemicals used in the studies were obtained from standard sources and were used without 
further purification. In all experiments water was ultrapurified Millipore® water (Millipore, 
Molsheim, France). The main materials including model drug compounds and stabilizers can be 
seen below. 
4.1.1 Model drug compounds  
Three poorly water-soluble drug compounds were chosen as model drugs in the studies. The most 
important physicochemical properties are given in Table 6. 
Table 6 List of the model drug compounds, their basic properties and corresponding publications. 
API Mw 
(g/mol) 
pKa Solubility  Reference Used in 
Indomethacin (IND)  357.8 4.5 14 µg/ml (pH 5)  [194] I, II, III 
Itraconazole (ITR) 705.6 3.7 < 1 µg/ml  [195] I 
Brinzolamide (BRA) 383.5 5.9 & 8.4 0.9% (w/v) (pH 5) 





4.1.2 Stabilizers  
Five different stabilizers were chosen for the milling process. Poloxamer 188 (Pluronic® F68) (I-
IV) and poloxamers 407 (Pluronic® F127) (I, IV) were obtained from BASF Co. (Ludwigshafen, 
Germany). Polysorbate 80 (Tween® 80) (I, IV) was from Fluka Chemika (Buch, Switzerland). 
Polyethylene  glycol  (PEG)  of  Mw 6000  g/mol  was  from  Sigma  (St.  Louis,  MO,  USA).  
Hydroxypropyl methylcellulose (HPMC) (Methocel®,  E5  Premium  LV  EP)  (IV) was from Dow 
Chemical Company (Michigan, USA). 
4.2 Preparation of nanosuspensions (I-IV) 
Nanosuspensions were prepared using the wet pearl milling technique. The stabilizer was dissolved 
in milling medium to form a stabilizer solution. A certain amount of drug compound was dispersed 
in  the  stabilizer  solution.  Then  the  drug  dispersion  was  poured  into  a  milling  vessel  containing  
milling pearls (zirconium oxide). Two milling vessels having an identical weight or one milling 
vessel with its weight counter were fixed in a milling machine (Pulverisette 7 Premium, Fritsch Co., 
Idar-Oberstein, Germany). The maximum pearl amount and maximum milling speed were used 
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depending  on  the  size  of  the  milling  pearls.  For  milling  pearls  with  the  diameters  of  1,  5  and  10  
mm, the maximum speeds were 1100, 1000 and 850 rpm, respectively. One milling cycle was set to 
3 minutes and there was a 15 min pause between each milling cycle for cooling down the milling 
vessels. Nanosuspensions were obtained after grinding and separated from the milling pearls by 
pipetting. Information about the amount of drug and stabilizer, and milling parameters can be seen 
in Table 7.  
Table 7 Detailed information about the amount of API and stabilizer, and milling parameters used 




Stabilizer type and 
amount (g) 
















IND (2) PEG, Tween 80, F68, 
F127 
 (0.2, 0.5, 1.2, 1.6) 
Water (10) 45 1  70 g 2, 6 and 10 I 
ITR (2) PEG, Tween 80, F68, 
F127 
 (0.2, 0.5, 1.2, 1.6) 
Water (10) 45  1 70 g 2, 6 and 10 I 
IND (2) F68 (1.2) Water (10) 45  1 70 g 10 II 
IND (1) F68 (1.2) Water (5) 20  1  30 g 10 III 
5 80 pcs.   
10 10 pcs.   
BRA (1) Tween 80 (0.5), HPMC 
(0.5), F68 and F127 (1.2)  
PBS (pH 4.5 
& 7.4) (5) 
20  1 30 g 6 or 10 IV 
4.3 Formulation of nanosuspensions 
Indomethacin nanosuspensions were converted to dried powders for inhalation or oral drug delivery 
(II). Mannitol (Alfa Aesar) 20 g/l and/or L-leucine (Alfa Aesar) 10 g/l were dissolved in the diluted 
nanosuspensions with the final drug concentration of 5 g/l. The mixed precursor was dried using an 
aerosol flow reactor (AFR) method [196, 197]. Briefly, the precursor suspensions were atomized 
using a modified air-jet atomizer (Collision atomizer, TSI model 3076) (TSI Inc. Particle 
Instruments, St. Paul, USA). To produce micron-sized droplets, the opposing impaction wall in 
atomizer was removed. The precursor suspensions were passed through a heated tubular aerosol 
reactor by nitrogen gas with a flow rate of 3 l/min. The total residence time of the aerosol in the 
reactor was 9 s. The temperature of the reactor was controlled with four separated heating blocks 
and two sets of temperature profiles from aerosol entry to exit were tested to dry the suspensions: 
100-100-100-100 oC (AFR 100) and 100-100-100-160 oC  (AFR  160).  The  residence  time  of  the  
aerosol in the zone at 160 oC was 1.5 s. The dried particles were diluted in a porous tube diluter 
with nitrogen (20 oC)  in  a  ratio  of  1:10  before  collecting  the  size-exclusively  particles  with  a  
Berner-type low pressure impactor onto aluminum foils. 
Brinzolamide nanosuspensions milled in two different pHs of phosphate buffered saline (PBS) 
were formulated into 3 kinds of eye drops for ocular drug delivery (IV). Excipients, including 
benzalkonium chloride (BAC) as preservative and possible polysorbate 80 as absorption enhancer 
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were added in the diluted nanosuspensions with PBS solutions. In three formulations, the final 
concentrations  of  brinzolamide,  HPMC,  BAC  and  Polysorbate  80  were  1,  0.25,  0.01  and  0.25  
w/v%, respectively. The physical mixtures of bulk drug and stabilizer in PBS (pH = 7.4) was 
prepared for in vitro negative control. 
4.4 Characterization techniques and dissolution modeling 
4.4.1 Size and size distribution (I-IV)  
The particle size and size distribution of nanosuspensions were measured by dynamic light 
scattering (DLS) using a Malvern Zetasizer 3000HS (Malvern Instrument, Malvern, UK) (I-IV). 
Polydispersity index (PI) was used to indicate the width of particle size distribution. The lower the 
PI value, the more uniform and monodisperse the particles are. Before the DLS measurement, a part 
of nanosuspensions were sonicated for 3-4 min and diluted by saturated drug solution to a suitable 
concentration for DLS measurement. The drug saturated solution was prepared by filtration through 
a 0.22 µm filter membrane (Pall Co. Mexico) of the raw drug suspensions in the same milling 
medium containing 0.1% (w/v) same stabilizer with the nanosuspensions after 24 h of shaking 
equilibration. The analyses were performed with a dispersant refractive index of 1.33, and the 
viscosity of the dispersion medium was 0.89 cP. The measurements were repeated 3 times for each 
sample.   
The particle size distributions of the aerosols were measured from gas phase at the aerosol 
reactor downstream using a TSI scanning mobility particle sizer equipped with a long differential 
mobility  analyzer  (TSI  model  3081)  (TSI  Inc.  Particle  Instruments,  St.  Paul,  USA)  and  a  
condensation particle counter (TSI model 3022) (TSI Inc. Particle Instruments, St. Paul, USA) (II). 
Geometric standard deviation (g.s.d.) was used to describe how spreads out the values are in the 
distribution. The low values of geometric standard deviation means the monodisperse aerosols 
having narrow size distributions. 
 4.4.2 Morphology (I, II and IV) 
Morphological evaluation of drug nanoparticles was conducted through transmission electron 
microscopy (TEM) (FEI Tecnai F12, Philips Electron optics, Holland) and scanning electron 
microscopy  (SEM)  (JSM-7500F,  JEOL  Ltd.,  Japan).  For  TEM  sampling,  diluted  samples  of  IND  
and ITR nanosuspensions (I) were pipetted on formvar film-coated 300 mesh copper grids (Agar 
Scientific,  Essex, UK) and dried at  the room temperature before analyses.  For SEM sampling, the 
dried IND nanopowders (II) and BRA nanosuspensions (IV) were placed or pipetted on a carbon-
coated double-sized tape. The nanosuspension samples were dried at an ambient condition before 
next  step.  The  samples  were  coated  with  platinum  in  a  sputter  coater  (Q150T  Quomm,  Turbo-
Pumped Sputter Coater, China) and then imaged by SEM. 
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4.4.3 Drug content (II, III and IV) 
After milling, collecting and drying of nanosuspensions, the true content of drug compound was 
different  from  the  theoretical  one.  To  quantify  the  exact  drug  content  in  the  nanosuspensions  or  
dried powders, a certain amount of IND nanosuspensions (I) were dried in an oven and then 
dissolved in ethanol (I), directly dissolved in ethanol without drying (III), or a known amount of 
dried IND powder (II) was dissolved in ethanol: water mixture (1:1, v/v). After complete 
dissolution, the IND solution was diluted by water (I) or ethanol/water (1:1, v/v) (II, III) for high 
performance liquid chromatography (HPLC) analysis. A certain amount of ITR nanosuspensions (I) 
were dried in an oven and dissolved in methanol, and finally diluted by methanol: water (1:1, v/v) 
prior to HPLC analyses. For BRA content determination (IV), a constant volume of suspensions 
was pipetted, dissolved in PBS (pH 7.4) and diluted by the same solution for HPLC analysis. 
HPLC instrument (Agilent 1100 series, Agilent Technologies, Germany) was used for 
quantification the drug concentrations. The parameters can be seen in Table 8. The injection volume 
of sample was 20 µl for all sample measurements. 
Table 8 Parameters of HPLC analyses for drug concentrations. 
API Column Mobile phase A Mobile phase 
B 






IND Luna 3µ 
C18 100A 
0.2% phosphoric acid in water 
(pH 2.0) 
acetonitrile 60:40 1.5 320 
IND Gemini NX 3µ 
C18 110A 
0.2% phosphoric acid in water 
(pH 2.0) 
acetonitrile 65:35 1 320 
ITR Gemini-NX 3µ 
C18 110A 
0.1% trifluoroacetic acid in water acetonitrile 55:45 1 261 
BRA Zorbax Eclipse 
XPD-C18 
acetonitrile/acetic acid/MQ water/ 





96:4 1 254 
4.4.4 Dissolution studies (I-IV) 
Different  dissolution  conditions  were  set  up  for  dissolution  tests  with  different  purposes.  Sink  
conditions were used for comparisons of nanoformulations and raw materials. The dissolution 
profiles of IND and ITR suspensions after milling, before milling and pure bulk drugs were studied 
in  phthalate  buffer  (pH  =  5.0)  and  0.1  M  HCl  aqueous  solution,  respectively  (I). The dissolution 
behaviors of IND nanosuspensions, dried nanosuspensions, physical mixtures and raw IND 
compound were compared in phthalate buffer (pH = 5.0) (II). Dissolution tests were performed 
using a rotating paddle apparatus according to the European Pharmacopoeia with an Erweka DT-06 
dissolution system (Heusentamm, Germany) at 37 oC and rotating speed of 100 rpm in 600 ml of 
their corresponding dissolution medium. A known amount of samples were introduced to the 
dissolution medium to maintain sink conditions. At predetermined time intervals, 5 ml of 
dissolution  medium  was  withdrawn  and  the  same  volume  of  pre-thermostated  fresh  medium  was  
added. The 1 ml of samples were immediately centrifuged at  13 000 rpm for 8 min to remove the 
undissolved particles. The drug concentration in the supernatant was analyzed by HPLC. All 
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experiments were performed at least three times, and the average values and standard deviations 
were calculated to form the dissolution profiles. 
Dissolution tests for BRA nanocrystal formulations were performed using the same paddle 
equipment (IV). PBS buffer (0.9% (w/v) sodium chloride in 10 mM phosphate buffer, pH 7.4) of 
500 ml at 37 oC was used as the dissolution medium. The exact amounts of the nanoformulations (I-
III) were dispersed in the dissolution medium with an agitation speed at 100 rpm. The sink 
conditions were maintained during the dissolution process. At specific time points, a constant 
volume of the dissolution medium was withdrawn and replaced by a fresh medium. The dissolution 
profiles of commercial product Azopt® and formulation with bulk BRA were investigated as 
controls. The BRA concentration was determined using HPLC method.  
To discriminate the dissolution profiles of nanosuspensions with different particle sizes, various 
dissolution conditions were investigated, such as the dissolution medium (hydrochloric acid 
medium, pH = 1.2 and phthalate buffer, pH = 5.0), agitation speed (50 and 120 rpm) and sample 
amount ratio (1/4, 1 and 3) (III).  Here,  the  sample  amount  ratio  was  defined  as  the  total  sample  
amount introduced in the dissolution medium to its apparent saturation solubility. The dissolution 
equipment was the same one with the experiments described above. A certain amount of sample 
was transferred into the dissolution medium of 600 ml at 37 oC. At certain times (0.5, 1, 2, 4, 6, 15 
and 30 min),  5 ml of dissolution medium was pipetted out and replaced with the same volume of 
pre-thermostated fresh medium. The samples were filtered through Acrodisc® syringe filters with 
0.2  µm  GHP  membranes  (PALL  Life  Science,  Ann  Arbor,  MI,  USA)  to  remove  the  undissolved  
particles. To avoid the possible absorption of IND molecules on the filter membrane, the first 4.5 ml 
of filtrate was discarded. The last 0.5 ml filtrate was analyzed by HPLC. 
To chart the dissolution profiles in non-sink conditions, the dissolved drug amount (%) is 
calculated according to the equation (1):  
         ?????????????????(%) = 100?× ? ?? ????? ?            (1) 
In conventional dissolution tests (sink conditions), the maximum concentration value (cmax) is 
equal to the total drug amount introduced to the dissolution medium (ctot). In our developed method 
(non-sink conditions), if ??? 1 the cmax is equal to ctot; and if ? > 1 the cmax is equal to the apparent 
saturation solubility (cs). cb is the bulk concentration of the drug. The ? introduced here is 
calculated according to the equation (2), which means the sample amount ratio, i.e. a ratio of the 
sample concentration in the dissolution medium to the apparent saturation solubility of the sample. 
          ? = ??? ??
??
?     (2) 
where W0 is the total drug mass in the dissolution medium, and V is the volume of the dissolution 
medium. cs was determined for each particle size fraction by shake flask method.  
4.4.5 Dissolution modeling (III) 
Based on a shrinking-core model and after a series of equation conversions, a relationship between 
particle radius and sample amount ratio was established. The equation (3) is introduced as follows: 
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??? ? ?? ?
?
??
???                       (3) 
where, Ri is  the  radius  of  the  particle,  D is  the  diffusion  coefficient  of  the  drug  in  water,  ? is  the  
density of the drug particles and W is the mass of the particles in the system at a given time point. 
The mass was calculated as a sum of the masses of particles. 
The equation were evaluated for a simulated normal size distribution for 10000 particles for 
1800 times steps (1 step = 1 s, total simulation time was 30 min). In all calculations, D was assumed 
to be 2 × 10-6 cm2s-1, cs were 1 µg/ml, and ? was 1.37 g/cm3. The particle population with radius of 
200 nm (R0) and standard deviation (?R = 0.15R0)  was  simulated.  To  model  the  bimodal  size  
distribution particle populations were simulated as above, but at the same time 5% of particles with 
twice as large a radius were added to the overall population. All calculations were done using 
standard mathematical software (Matlab) by numerically evaluating the equation using the Euler 
method for all the simulated particles in each time step. 
4.4.6 Stability of nanosuspensions (I) 
Stability of nanosuspensions was studied after storage for 2 months at room temperature (25 oC) 
and 4 oC.  For  physical  stability,  the  particle  size,  size  distribution  and  morphology  of  
nanosuspensions were checked during the storage period by DLS and TEM methods. For chemical 
stability, the drug concentrations of nanosuspensions were monitored during the storage by HPLC. 
Any decrease in the area of the drug peak or occurrence of extra drug peak in chromatograms was 
considered as chemical instability. 
4.4.7 Solid state analyses (I, II and IV) 
For solid state analysis nanosuspension were freeze-dried (FTS Lyostar II freeze drying system, SP 
Industries Inc., Warminster, USA). Primary drying was performed in -30 oC for 17 hours and 
secondary drying was done stepwise from -25 oC to 45 oC.  Thermal  analyses  of  the  dried  
nanosuspensions were carried out with a differential scanning calorimeter (DSC) (DSC 823e, 
Mettler Toledo Inc., Greifensee, Switzerland). Before measurements, the DSC was calibrated using 
gallium, indium and tin. Sample powders from 2 to 6 mg were placed in perforated aluminum 
sealed pans. An identical pan was used in the machine as reference pan. The samples were heated in 
a temperature range from 25 oC to 180 oC (IND) or 200 oC (ITR) or 310 oC (BRA), depending on 
the melting points of drug compounds and excipients with a heating rate of 10 oC /min. The 
measurements were performed under the nitrogen flow of 50 ml/min. Pure drug, each excipient and 
physical mixtures were also tested as controls under the same conditions corresponding to its dried 
nanosuspensions. The data were analyzed with STARe software (Mettler Toledo, Greifensee, 
Switzerland). 
X-ray powder diffraction (XRPD) diffractograms of each of the excipients, pure drug, dried 
powder before milling and after milling were recorded using an X-ray diffractometer (Bruker AXS 
D8, Karlsruhe, Germany) (I and II). The measurements were performed in symmetrical reflection 
mode with Cu-K? radiation ? = 1.54Å (40 kV voltage and 40 mA current). The samples was placed 
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on a flat aluminum sample holder and scanned from 5° to 40°, 2? with a step size of 0.02°, and the 
measuring time was 0.5 s/step. 
4.4.8 In vivo experiments (IV) 
Seven-month  old  male  Wistar  rats  (n  =  44,  weight  406-601 g;  Harlan  Laboratories  B.V.,  Venray,  
The Netherlands) were used in animal study. The experimental procedures were approved by the 
Finnish National Animal Ethics Committee in State Provincial Office of Southern Finland. The 
animal study was performed according to the European Communities Council Directive 
(86/609/EEC) and the guidelines published by the Institute for Laboratory Animal Research.  
Prior to in vivo tests, ocular hypertension in one eye of each rat was induced as laser method 
[198]. Finally 36 rats successfully infected a reasonable range of intraocular pressure (IOP) were 
used for in vivo tests. Fifteen hours after the laser treatment, the rats were anesthetized with the 
mixtures of ketamine and medetomidine, and a dose of 10 µl from each formulation was instilled in 
the lower conjunctival sac of laser-treated eyes. The treatment groups were as follows: formulation 
I (n = 5 rats), formulation II (n = 5), formulation III (n = 6), Azopt® (n = 6), 0.9% NaCl (n = 8) and 
non-treated group (NT, n = 6). The IOPs were measured prior to drug administration and after the 
administration at different time intervals (7.5, 15, 30, 45 and 60 min) using an Icare Tonolab 




5 Results and discussion 
5.1 Preparation and characterization of nanosuspensions (I, III) 
Though nanocrystal technologies, like wet milling, are considerably simple processes for particle 
size reduction, nanocrystal development requires multidisciplinary knowledge, including the 
breakage kinetics of nanocrystals, dynamic equilibrium between the particle breakage and 
aggregation, stabilization mechanisms of stabilizers, formulation processing and affecting fates in 
vivo [4, 77]. The fundamental and essential complementary research should be developed and 
performed in order to obtain the nanocrystals successfully. In this thesis, the effects of milling 
parameters, such as the milling time, diameter of milling pearls, stabilizer type and concentration, 
on the particle size, size distribution and stability were investigated on three different model drugs. 
5.1.1 Influencing factors on particle size 
5.1.1.1 Effect of milling time (I, IV) 
The mean particle sizes and PIs of milled indomethacin and itraconazole suspensions with different 
milling cycles are shown in Fig. 6. For all stabilizers, the concentration was kept 25% relative to the 
drug amount. Generally, decreasing trends in particle sizes and PIs were found with increasing 
milling time, except for the case of PEG as stabilizer. After only 2 milling cycles, the average 
particle sizes of both drugs were dramatically decreased below 1 µm since pharmaceutical 
compounds have low hardness, which is easy for grinding. Fine nanosuspensions with smaller and 
more uniform particle sizes were obtained with longer milling times. Long milling time provides 
more  energy  input  to  break  the  particles  into  smaller  ones  and  provides  sufficient  diffusion  and  
absorption time for stabilizer molecules to attach onto the particle surfaces. Further increase in 
milling time did not remarkably decrease particle sizes or they even increased in the case of 
indomethacin nanosuspensions with F127 as the stabilizer. The same phenomenon was also found 
in milling process of 10-hydroxycamptothecin suspensions using the high pressure homogenization 
[61]. For brinzolamide compound, the milling process was stopped after 6 cycles since the good 







Figure 6 Mean particle sizes and PIs of the suspensions with the same stabilizer concentration 
(25% drug content), as a function of milling cycle. Indomethacin suspensions (left) and itraconazole 
suspensions (right). C2, C6 and C10 in the ?gure mean after 2, 6 and 10 milling cycles of 3 min each 
(from paper I). 
5.1.1.2 Effect of stabilizer type and concentration (I, IV) 
The choices of stabilizer type and concentration are important in nanosuspension preparation. The 
mean particle sizes and PIs of indomethacin and itraconazole as functions of stabilizer type and 
concentration after 10 milling cycles are shown in Fig. 7. For both drugs, PEG failed to stabilize the 
nanosuspensions. PEG is a linear hydrophilic homopolymer. Interactions between the drug and 
stabilizer, such as hydrophobic interactions, hydrogen bonds and ionic interactions, are the main 
driving forces for stabilizer adsorbing on the drug particle surfaces. Shortage of hydrophobic 
moieties  and  other  functional  groups  in  PEG  chains  are  major  problems  for  absorption.  It  was  
reported that for a hydrophobic drug, an effective stabilization performance of copolymers requires 
the hydrophobic moiety content to be higher than 15 mol%, if there are no functional groups in the 
polymer suitable for interactions with the drug [71, 73]. In addition, PEG is a hydrogel polymer, 
which can imbibe water and swell to gel. Thereby, the slurry of the drug, PEG and water is in paste 
form and exhibits a very high viscosity. The high viscosity of suspensions hinders the movement of 
milling pearls and energy transfer [81], thereby reducing the milling efficiency. 
For indomethacin nanosuspensions, the finest nanosuspensions were obtained with the mean 
particle sizes of 345 nm, 375 nm and 723 nm stabilized by F68 (80%), F127 (60%) and Tween 80 
(25%), respectively (Fig. 7 a). F68 was the most effective stabilizer, followed by F127 and Tween 
80. Pluronic® F68 and F127 are linear triblock ABA non-ionic copolymers (A stands for 
hydrophilic polyethylene oxide (PEO) segment and B stands for hydrophobic polypropylene oxide 
(PPO) segment). It was clearly confirmed that the hydrophobic PPO chains act as driving forces for 
absorption on particle surfaces, while the PEO chains form hydrophilic layers surrounding drug 
particles to sterically protect against aggregation [79]. In contrast to F127, F68 was more effective 
for particle size reduction since F68 has a lower molecular weight which may exert less kinetic 
restriction in the adsorption process and faster diffusion [79]. Moreover, nanosuspensions exhibited 
a good stability for two months with both polymers as stabilizers. For the surfactant Tween 80, the 
nanosuspensions with a larger particle size and PI were achieved compared to the polymers. 
Furthermore, the nanosuspensions were not stable during the 2 months storage, i.e. the mean 
particle size was decreased from 986 nm to 736 nm and the PI was increased from 0.37 to 0.62. 
Tween 80 is a smaller surfactant molecule, which effectively decreases the interfacial tension of the 
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particles but forms a thin protective outer layer. The thin layer is insufficient for the particle 
stability. In addition, Tween 80 can remarkably increase the solubility of indomethacin and thus 
prompt the Ostwald ripening [28].  
For itraconazole nanosuspensions, the smallest particle sizes were generated when 60% of F127 
was used as stabilizer, and then followed by 25% Tween and 25% F68. Here, F68 was worse than 
F127 for particle size reduction and stability, which might be contributed to stronger hydrophobic 
interactions between F127 and drug particles. Moreover, a slurry with a high viscosity was formed 
when F68 and itraconazole were mixed, which is not beneficial for milling. Comparing the two 
drugs, the different milling results were potentially caused by the intrinsic properties of the drugs, 
such as hardness, hydrophobicity and crystal shape [42]. 
 
Figure 7 Mean particle sizes and polydispersity indexes (PIs) of the suspensions with different 
stabilizers and stabilizer concentrations after milling for 10 cycles. Indomethacin suspensions (left) 
and itraconazole suspensions (right) (from paper I). 
For preparation of brinzolamide nanosuspensions, four types of stabilizers, including F127, F68, 
polysorbate 80 and HPMC, were screened. The most optimal stabilizer conditions were HPMC with 
a concentration of 25% relative to the drug amount. HPMC containing a high degree of substitution 
of the methoxy and hydroxypropoxy groups can effectively adsorb on the drug particles by 
hydrogen bonding, which prompts the particle size reduction during the milling and protects the 
particles against aggregation [69].  
5.1.1.3 Effect of milling ball diameter (III) 
As shown in Table 9, the indomethacin nanosuspensions with different particle sizes and PIs were 
prepared depending on the diameters of milling pearls. The particle size and PIs of suspensions 
were decreased with the decreasing diameter of milling pearls. Small size of milling pearls supplies 
more contact points and larger contact surface area between milling pearls and drug crystals, which 





Table 9 Particle size, polydispersity index, and apparent saturation solubility of indomethacin 
nanosuspensions milled with different sized milling balls (n = 3, milling for 10 cycles) (from paper 
III). 
 






340 ± 4 
560 ± 11 
1300 ± 111 
 
PI 





1.29 ± 0.03 
1.23 ± 0.06 
1.15 ± 0.01 
pH 5.0 
21.23 ± 0.19 
19.25 ± 0.39 
18.06 ± 0.43 
In summary, the particle sizes decreased fast within the first 2 cycles as the large micron-sized 
drug particles were easier to break. As milling continued, the apparent breakage rate decreased, and 
the particles became smaller and more homogeneous. The smaller diameter of milling pearls leaded 
to fine nanosuspensions. Stabilizers play a major role in particle reduction and stabilization of the 
milled drug particles.   
5.1.2 Morphology evaluation (I, IV) 
The TEM images of itraconazole micro/nanosuspensions milled with four different stabilizers can 
be seen in Fig. 8 (A-D). Microparticles were observed when PEG was used as the stabilizer in the 
milling  process,  and  this  result  is  well  in  agreement  with  the  DLS  results.  For  stabilizer  F127,  
itraconazole nanocrystals kept their original rod-like shape as bulk materials. However, for 
stabilizer Tween 80, the crystal shape changed from rod-like to cubic-like, which might be 
attributed to the surfactant molecules adsorbing on crystal surfaces and then changed the crystal 
shape. The similar findings reported by Mou et al. [34] showed that itraconazole nanocrystals 
prepared using an acid-base neutralization method exhibited a rod shape with F127 as a stabilizer 
but a spherical shape with HPMC. For stabilizer F68, the nanocrystals were found to aggregate. 
The morphologies of indomethacin nanocrystals with stabilizers F68 and Tween 80 are shown in 
Fig. 8 (E-F). The angular surfaces of crystals were transformed to smooth round surfaces after 
milling. The gray layers around the particles were considered to be due to the polymer or surfactant. 






Figure 8  TEM images of suspensions: (A-D) itraconazole stabilized by the F127, F68, Tween 80 
and PEG; (E-F) indomethacin stabilized by the F68 and Tween 80. The stabilizer concentration is 
25% relative to the drug amount (from paper I). 
The morphology of brinzolamide nanosuspensions stabilized by HPMC in pH 7.4 was imaged 
using SEM (Fig. 9). The mean particle size of brinzolamide nanosuspensions detected by SEM (Fig. 
17 A-B) is well in agreement with the findings of the particle size measurements based on DLS. A 
rod-like big crystal in Fig.9A was considered to the crystallization of free BRA from the liquid 
phase during the sample preparation. 
 
Figure 9 SEM (images with different magnifications) of brinzolamide nanocrystal suspension (pH 
7.4) stabilized by HPMC, scale bars being 1 µm and 10 µm, respectively (from paper IV). 
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5.1.3 Dissolution studies 
5.1.3.1 Comparisons of milled and unmilled suspensions (I, IV) 
In order to compare the dissolution profiles of milled and unmilled suspensions, sink conditions 
were used to enhance the dissolution rate of poorly water-soluble drug compounds. The dissolution 
profiles of the milled suspensions, physical mixtures and pure drug materials are shown in Fig. 10. 
Compared to the suspensions of physical mixtures and pure drugs, milled suspensions of both drugs 
displayed a significant increase in dissolution rate and the dissolutions were completed in a few 
minutes. A large surface area-to-volume and higher apparent saturation solubility of nanocrystals 
pronouncedly enhance the dissolution rate according to the Noyes-Whitney equation. It is worth 
noting that the milled suspensions with quite different average particle sizes (300 nm to several 
micrometres) depending on the stabilizers used generated very similar dissolution profiles. Sink 
conditions cannot discriminate between the dissolution profiles of the milled samples. The same 
dissolution behaviours were found for brinzolamide samples.  
 
Figure 10 The dissolution pro?les of indomethacin (left) and itraconazole (right) from 
nanosuspensions (open symbols), physical mixtures and pure drug (solid symbols) with 25% 
stabilizer (from paper I). 
5.1.3.2 Comparisons of milled suspensions (III) 
As mentioned above, sink conditions can effectively discriminate between the dissolution profiles 
between nanosuspensions and raw materials, but fail to see differences between nanosuspensions. 
Therefore, a discriminating dissolution method using non-sink conditions was investigated. Firstly, 
the dissolution behaviours of nanosuspensions were simulated in silico. The changes in particle 
mass  fraction  profiles  at  various  dissolution  times  and  with  different  sample  amount  ratio  (?)  are  
shown in Fig. 11. For the monomodal particle population (average radius was 200 nm) (Fig. 11, 
left), all particles vanished after around 1.5 min in sink conditions (? = 0.1). With increasing ? 
values,  the  completion  of  dissolution  process  needed  a  longer  time.  The  longest  dissolution  time  
was occurred when ? = 1. Further increased the ? value to 3, the peak of profiles shifted to left side, 





smaller  after  dissolution.  The  profiles  at  dissolution  time  points  of  1.5,  3,  7.5  and  15  min  
overlapped, implying that the dissolution process was stopped in a short time (1.5 min). For the 
bimodal particle populations (200 nm/ 400 nm, 95%/5% of the particle population) (Fig. 11, right), 
the slowest dissolution rate was observed at ? = 1. At sink conditions (? = 0.1), the smaller particles 
dissolved fast and the larger particles became smaller. When ? = 3, only a part of the smaller 
particles dissolved and the larger particles never changed in size. The dissolved smaller particles 
saturated the dissolution medium and large particles could not dissolve anymore in a saturated 
solution. 
 
Figure 11 Mass weighted graphs of particle populations during the dissolution simulations. 
Parameters for the simulation of monomodal were ?R = 0.15R0 and R0 = 400 nm (left). Parameters 
for the simulation of bimodal were ?R= 0.15R0 and R0 = 200 nm (95% of the population)/400 nm 
(5% of the population) (right). The arrows indicate the curves at later time points (from paper III). 
The time to achieve 90% of the maximum extent of dissolution/saturation for particle 
populations with average sizes of either 200 nm or 400 nm and bimodal distribution as a function of 
? are  shown  in  Fig.  12.  In  the  case  of  ? <  1,  i.e.  the  concentration  of  sample  in  the  dissolution  
medium is below its apparent saturation  solubility,  all  particles  in  three  samples  would  be  
completely dissolved, but the dissolution time was different. The smaller the particle size, the 
shorter dissolution time was needed. The time curve of the bimodal sample was between the ones of 
samples with 200 nm and 400 nm. In the case of ? > 1, i.e. the amount of sample in the dissolution 
medium is above its apparent saturation solubility, the dissolution medium finally becomes 
saturated during a dissolution experiment. The trend of bimodal curve was close to the sample with 
the radius of 200 nm since the dissolution was mostly due to the small particles and the presence of 
the larger particles did not make a difference for the dissolution rate, which was confirmed by 






Figure 12 Plots of simulated times to achieve 90% of dissolution/saturated solubility for 200 nm, 
400 nm (particle radius), and bimodally distributed particles (5% larger particles) as a function of 
? (from paper III). 
Secondly, the dissolution tests of nanosuspensions with three different particle sizes were 
carried  out  as  a  function  of  sample  amount  ratio  using  paddle  apparatus  (Fig.  13).  The  sample  
amounts introduced into the dissolution media were calculated based on their solubilities (Table 9). 
As expected based on the simulations, the most discriminating dissolution profiles between the 
three nanosuspensions were found at ? = 1, since the slowest dissolution rate occurred at this 
condition. Significant differences were found especially at the beginning of the dissolution 
processes. 
The weak discrimination in dissolution profiles were obtained at sink conditions because the 
rapid dissolution masked the differences that resulted from particle sizes. The same weak 
discrimination  was  found  when  the  value  of  ? was  larger  than  1,  since  the  fast  dissolution  was  
mainly caused by the large number of smaller particles and the solution became saturated quickly, 
which  was  already  proofed  by  the  simulations  (Figure  11).  Besides  the  sample  amount  ratio,  the  
effects of the dissolution medium pH and agitation speed on dissolution rate were investigated. 
Lower solubility by choosing a proper pH of the dissolution medium was helpful in getting 
discriminating dissolution profiles, whereas the agitation speed had little influence on the 










Figure 13 Dissolution profiles of different suspension amounts (?) when the dissolution medium 
and agitation speed were fixed at pH 1.2 and 120 rpm at 37°C. (a) ? = 1/4, (b) ? = 1, (c) ? = 3. 
Square, round, and triangle symbols stand for the suspensions with particle size 340, 560, and 1300 
nm, respectively (n = 3 – 6) (from paper III). 
5.1.4 Evaluation of the crystalline state (I, II and IV) 
To characterize the solid state of freeze-dried nanosuspensions, DSC and XRPD studies of the 
drugs, stabilizers, physical mixtures and freeze-dried nanosuspensions were performed. The DSC 
thermographs of indomethacin samples are shown in Fig. 14 (left). The curve of pure indomethacin 
exhibited a single sharp endothermic peak at onset temperature of 160 oC, due to its melting point. 
Stabilizer F127 showed also a single melting peak with onset temperature at around 54 oC. 
Compared to the physical mixtures, indomethacin melting peak of milled samples showed a little bit 
shift to a lower temperature, which caused by the reduction of particle size or the presence of the 
stabilizer [30, 200]. No baseline shift corresponding to glass transition or peaks for recrystallization 
appeared, indicating that amorphous form of indomethacin was not produced during the milling and 
freeze drying processes. 
The X-ray diffractograms are shown in Fig.14 (right). Raw indomethacin exhibited crystalline 
state. There are no apparent differences in the X-ray patterns between the physical mixtures and 
milled samples. Low diffraction peak intensities in the milled samples were attributed to the 
dilution of the particles with the stabilizer [51].  For the samples of itraconazole and brinzolamide, 
the  crystalline  state  was  kept  after  milling.  As  a  conclusion,  combining  the  results  of  DSC  and  






Figure 14 (Left) the DSC patterns of IND, from up to down: milled sample, physical mixtures, pure 
F127 and bulk drug. (Right) X-ray analyses of IND from up to down: F127, bulk drug, physical 
mixtures and milled sample (from paper I). 
5.2 Formulation of nanosuspensions (II, IV) 
The merits of nanocrystals, including increased surface-to-volume ratio, improved solubility, fast 
dissolution, enhanced adhesiveness and potential targeted drug delivery, provide huge opportunities 
for drug delivery. In the past twenty years, there has been a considerable research interest in various 
nanocrystal technologies related to the production of drug nanocrystals and their in vitro physical 
and chemical properties. Nowadays, in vivo behaviours of the nanocrystals have been generally 
studied [201]. The drug nanocrystals can be used as a versatile formulation platform, such as oral, 
parenteral, ophthalmic, transdermal and pulmonary delivery, to alter and improve the 
pharmacokinetic, pharmacodynamics and targeting properties of poorly soluble drugs [201]. In this 
thesis, the microparticulate powders consisting of drug nanocrystals for oral or pulmonary drug 
delivery were formulated. In addition, the formulations of the brinzolamide nanosuspensions for 
ophthalmic administration were studied. 
5.2.1 Nanocrystals in micron-sized formulation (II) 
Nanocrystallization is a promising way to improve the dissolution rate of poorly water-soluble 
drugs, but handling the nanopowders in the production of the final formulation is problematic, due 
to their physical properties such as poor flowability, low density and aggregation tendency. 
Assembling the nanocrystals into microparticulate carriers is a potential way to solve the problems 
related to the small particles and at the same time to keep the high dissolution rate. The concept of 
“nanos-in-micros” is illustrated in Fig. 15. The carrier matrix of mannitol provides stable powder 
formulations, which are suitable for inhalation products or automated tablet manufacturing. The 
surface-active L-leucine forms crystalline coating layers around the microparticles during the 
aerosol drying process, which provides a protection for inner core, excellent aerosolization 








Figure 15 Illustration of the concept for producing and using nanostructured microparticles, 
nanos-in-micros. Wet-milled nanosuspensions are dried and embedded into a mannitol matrix and 
coated with a crystalline L-leucine layer in an aerosol flow reactor. Microparticle structure 
dissolves rapidly in water, and primary nanoparticles are released. Fast drug dissolution is due to 
the small size of the initial particles (from paper II). 
The compositions of precursor suspensions used for drying into microparticles are listed in 
Table 10. The amounts in compositions were based on previous studies and should result in micron-
sized particles with a crystalline L-leucine coating [203, 204]. Samples were dried using two 
different temperatures. The mass mean diameters of the six formulations ranged from 576 nm to 
956 nm. 
Table 10 Precursor Solution Compositions for AFR and Dry Powder Sizes of the Prepared 
Powders. Sizes are Mass Mean Diameters (from paper II). 
 Drying  Precursor solution content (g/l)  Powder size 
 T (oC) IND F68 Mannitol Leucine  Size (nm) g.s.d 
AFR 100-1 100 5 1.25 - -  956 1.7 
AFR 100-2 100 5 1.25 20 -  673 1.6 
AFR 100-3 100 5 1.25 20 10  824 1.5 
AFR 160-1 160 5 1.25 - -  714 1.6 
AFR 160-2 160 5 1.25 20 -  665 1.6 
AFR 160-3 160 5 1.25 20 10  576 1.4 
The images of size-excluded samples with D50 (mass-median-diameter) of 3.9 µm were 
evaluated by SEM (Fig. 16). The aerosol particles dried from indomethacin nanosuspensions 
without mannitol and L-leucine (AFR 100-1 and AFR 160-1) were physically unstable, i.e. 
aggregation/sintering of particles in AFR 100-1 (Fig. 16A) and re-crystallization of indomethacin in 
AFR 160-1 (Fig. 16D) was seen. The indomethacin nanocrystals with the onset melting temperature 
of 146 oC melted in the high aerosol temperature (160 oC) and then re-crystallized at the lower 
temperature. Mannitol alone (AFR 100-2 and AFR 160-2) protected the particles from aggregation 
to some extent, but still could not sufficiently stabilize the particle integrity, especially for AFR 
160-2 (Fig. 16E). With the L-leucine coating (AFR 100-3 and AFR 160-3), individual and 
integrated particles were obtained. L-leucine is a surface-active material which diffuses to the 
droplet surfaces and thus forms a crystalline surface layer around the particles after drying. In AFR 
160-3 samples (Fig. 16F), long needle-like crystals distributed around microparticles was owned to 
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the  partial  re-crystallization  of  indomethacin  during  the  drying  process.  For  the  samples  of  AFR  
100-3 and AFR 160-3, the indomethacin kept the crystalline state in the microparticles which was 
confirmed by DSC and XRPD.  
 
Figure 16 SEM images of aerosol flow reactor produced microparticles. Size-excluded samples 
with D50 of 3.9 ?m: AFR 100 – 1 (A), AFR 100 – 2 (B), and AFR 100 – 3 (C) and AFR 160 – 1 (D), 
AFR 160 – 2 (E), and AFR 160 – 3 (F). Needle-like particles are indomethacin crystals after being 
melted and recrystallized in the aerosol process (F) (from paper II). 
Drug loading in fractionated particle sizes of AFR 100-3 and AFR 160-3 samples are shown in 
Fig. 17. The AFR 100-3 had much lower drug amount in the smaller size fractions (<422 nm), 
while AFR 160-3 had higher drug amount in the smaller size fractions (<241 nm). It is reasonable 
and easier to understand for AFR 100-3 samples that the smaller particles contained low drug 
amounts as the particle sizes there were smaller than the particle size of the nanocrystals used. For 
the sample AFR 160-3, long and thin strips protruding from the particles were formed owing to the 
recrystallization of melted nanocrystals in 160 oC (seen in Fig. 16F). These crystalline strips were 
fragmented into smaller particles by the gas turbulence and particle collision. Small segments of 
strips were located in the impactor layer of the particles below 241 nm and lead to a high apparent 
drug contents. Total drug loadings in the two samples were not significantly different. For the AFR 
100-3 sample, the drug loading was 8.7% (w/w) and in the AFR 160-3 sample the loading was 






Figure 17 Indomethacin loadings (w-%) in the microparticles of different sizes (n =1-3) (from 
paper II). 
Dissolution curves of the nanosuspensions, aerosol dried nanosuspensions, physical mixtures of 
drug and stabilizer, and the pure indomethacin are given in Fig. 18. Both aerosol flow reactor dried 
samples appeared to have as fast dissolution as the fresh nanosuspensions and significantly 
improved dissolution rate compared to bulk indomethacin. The slightly slower initial dissolution (at 
first  2  min)  of  the  drug  from  the  aerosol  samples  was  attributed  to  the  disintegration  of  
microstructure. The re-dispersion testing supported the dissolution results. The particle size of fresh 
nanosuspensions was 485 nm with PI = 0.51. The re-dispersions of AFR 100-3 and AFR 160-3 in 
drug saturated solution showed the sizes of 490 nm (PI = 0.45) and 1330 nm (PI = 0.94), 
respectively. The AFR 100-3 preserved the nanoparticles and dissolved as fast as nanocrystals in 




Figure 18 Dissolution profiles of aerosol dried samples, indomethacin nanosuspension, physical 
mixtures and pure indomethacin (n=3) (from paper II). 
In summary, intact microparticles containing drug nanocrystals were achieved when mannitol 
and L-leucine as excipients were added and the precursor suspensions were dried in a low 
temperature. The dried powders (in low temperature) can disintegrate into nanoparticles and 
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dissolve as fast as nanocrystals in the aqueous medium. The “nanos-in-micros” powder is a novel 
tool for pharmaceutical formulations (e.g. tablet and pulmonary drug delivery) with fast-dissolving 
property.    
5.2.2 Nanosuspensions for ophthalmic delivery (IV) 
HPMC was chosen as the stabilizer for the preparation of brinzolamide nanosuspensions (BRA-
NPs) since it could effectively reduce the particle size and make the nanosuspensions stable. 
Moreover, HPMC as an inactive ingredient has been approved for ocular drug delivery, ophthalmic 
lubricant  and  tear  fluid  substitute  [205].  As  the  solubility  of  brinzolamide  is  affected  by  pH,  the  
nanosuspensions were prepared in two different pHs of PBS media (pH = 4.5 and 7.4). The particle 
sizes and PIs of nanosuspensions are shown in Table 11. The nanosuspensions were formulated in 
three  different  formulations.  The  compositions  of  the  formulations  are  listed  in  Table  11.  In  
formulation II, polysorbate 80 was added to enhance the drug permeation. The bulk drug was used 
as a negative control. 
 
Table 11 The compositions of the BRA nanocrystal formulations (I-III) and the negative control 
(the final composition concentrations in formulations are BRA, 1 w/v%; HPMC 0.25 w/v%; BAC, 
0.01 w/v%) (from paper IV).  
 Composition Particle size (nm)   PI 
Formulation I BRA-NPsa, pH 7.4 460 ± 10 0.21 ± 0.17 
  
BAC 
PBS, pH 7.4   
Formulation II BRA-NPsa, pH 7.4 460 ± 10 0.21 ± 0.17 
  Polysorbate 80 (0.25 w/v%)   
  
BAC 
PBS, pH 7.4   
Formulation III BRA-NPsa, pH 4.5 530 ± 2 0.12 ± 0.02 
  
BAC 
PBS, pH 4.5   
Negative controlb, bulk BRA, HPMC micronsizedc - 
  
BAC 
PBS, pH 7.4    
    (aBRA; 16 w/w%, bphysical mixture, cparticle size > 10 µm, outside the DLS detection limits) 
The IOP reductions as a function of time in the laser-treated eyes after topical administration of 
different formulations are shown in Fig. 19. Compared to the 0.9% NaCl and NT groups, the 
administration of formulation III significantly lowered the IOP when measured after 60 min in the 
laser-treated eyes (Mann-Whitney U test, P ? 0.004). The IOP lowering effects of formulations I 
and II and Azopt® in the laser-treated eyes after 60 min were equally significant when compared to 
the 0.9% NaCl group (P ? 0.019),  but not statistically significant when compared to the NT group. 
Comparing  to  the  formulations  I  and  II,  formulation  II  showed  a  little  bit  higher  IOP  than  
formulation I at each measurement time point, which is in contrast to our expectations. The 
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surfactant polysorbate 80 added in formulation II did not enhance the drug permeation and reduce 
the IOP further. Formulation III reduced IOP after 60 min more effectively than formulation II (P = 
0.017) and Azopt (P = 0.004), but the difference to formulation I was insignificant (P = 0.126). In a 
summary, the brinzolamide nanocrystal formulations were as good as, or even better than the 
commercial product Azopt® in IOP reduction.  
 
Figure 19 The IOP values as a function of time in the laser-treated eyes after topical application 
(BRA; 100 µg) of BRA nanocrystal formulations I - III and Azopt®. For comparison, the results 
after the topical application of 0.9% NaCl as well as the values for the non-treated group (NT) are 




The wet pearl milling technique is an effective and powerful tool to reduce the particle size of 
pharmaceutical drug compounds and manufacture nanosuspensions. For different drug compounds, 
the manufacturing parameters are different and should be optimized in order to obtain the smallest, 
most homogeneous and stable particles. The milling process, stabilizer and drug properties play 
important roles in milling results. Generally, the longer milling time leads to a smaller particle size 
with narrower particle size distribution. The stabilizer molecules fully covering drug particle 
surfaces through the hydrophobic or other interactions provide steric or electrostatic stabilization. 
Once the optimal preparation conditions are found out, the nanosuspensions were easily obtained 
with the small variation. The nanosuspensions exhibited a significantly increased dissolution rate 
compared to the micron-sized particles and good stability during storage period. The crystalline 
state was kept after milling. 
A discriminatory method for nanosuspensions was developed based on the compendial rotating 
paddle apparatus. The results of simulation and experiments indicated that when the sample amount 
in  dissolution  medium  was  close  to  the  apparent  saturation  solubility  of  the  drug,  the  slowest  
dissolution rate and the most discriminating dissolution curves could be obtained. This condition 
was possible to apply to nanoparticles with various particle sizes. Sink conditions lead to a 
relatively rapid dissolution, which masks the differences between dissolution profiles caused by 
particle sizes. An excessive amount of sample also produces rapid dissolution rate since the 
dissolution medium is quickly saturated by the quickly dissolving smaller particles. This 
discriminatory method is simple to perform and can be potentially used in any nano-product 
development and quality control studies. 
The “nanos-in-micros” particles were prepared using the combination of wet milling technique 
and aerosol flow reactor. Mannitol was used as the matrix and L-leucine as the coating layer, which 
protected the particles from aggregating/sintering. The drying process was temperature dependent. 
The primary nanoparticles did not survive at the higher processing temperature. The sample dried at 
the lower temperature would be suitable for further processing (e.g. tablet) and also suitable for 
pulmonary drug delivery after size fractionation. This “nanos-in-micros” concept can be as a tool 
for pharmaceutical formulation. 
Another drug compound (brinzolamide) in the form of nanocrystals was formulated for 
ophthalmic drug delivery to reduce the IOP. Nanosuspensions were successfully prepared in two 
different  pH values  with  HPMC as  the  stabilizer  using  the  wet  milling  method.  The  brinzolamide  
nanocrystal formulation exhibit a rapid dissolution rate in vitro, and a good ocular bioavailability in 
vivo. The efficacy in IOP reduction of nanoformulations is as good as, even better than the 
commercial product.  
As  a  summary,  this  thesis  represents  different  milling  conditions  for  nanosuspensions  of  three  
poorly water-soluble drug compounds. The wet milling technique offers the advantages of a high 
drug loading and less excipients requiring process and is a promising method for preparing drug 
nanosuspensions. Secondly, the pharmaceutical dosage forms of nanosuspensions, including dried 
powder for tablet or plumary delivery, and ocular nanosuspension were successfully developed. 
These formulations having the improved dissolution rates provide a potential opportunity in 
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